Abnormally high level of lipids in blood.
| Excerpt | Reference |
|---|
| "Type V hyperlipemia is not very common." | ( Beaumont, V; Buxtorf, JC; Jacotot, B; Schlesinger, M, 1979) |
| "Hyperlipemia is one of several risk factors for premature ischemic vascular disease." | ( Hazzard, WR, 1976) |
| "Treatment of hyperlipidemia is aimed at reducing the risk of atherosclerosis or arresting its course." | ( Lees, AM; Lees, RS, 1976) |
| "The hyperlipidemias are fairly common and require proper understanding." | ( Shakir, KM, 1976) |
| "Hyperlipidemia is a well-recognized complication of renal transplantation." | ( Belzer, FO; D'Alessandro, AM; Kalayoglu, M; Knechtle, SJ; Pirsch, JD; Reed, A; Sollinger, HW, 1992) |
| "Controlling hyperlipidemia is an important aspect in the treatment and prevention of coronary artery disease." | ( Kuhn, M; Milander, MM, 1992) |
| "Hyperlipidemia is a major risk factor for atherosclerosis and probably contributes to the increased cardiovascular mortality following renal transplantation." | ( Bailey, RR; Divakar, D; Frampton, CM; George, PM; Murphy, J; Walmsley, TA, 1991) |
| "Hyperlipidemia is prevalent in hypertension, but the cause of this association is unknown." | ( Ames, RP, 1991) |
| "Hyperlipemia is a very frequent complication of the diabetic patient on dialysis." | ( Barrientos, A; Coronel, F; De Oleo, P; Macia, M; Naranjo, P; Tornero, F; Torrente, J, 1991) |
| "Dyslipidemias are frequent in diabetic subjects: they increase the risk for atherosclerosis, in addition to the risk of diabetes mellitus per se." | ( Golay, A; Keller, U; Pometta, D, 1990) |
| "Hyperlipidemia is a consistent feature of the nephrotic syndrome." | ( Boulton-Jones, JM; Caslake, MJ; Dagen, M; Packard, CJ; Shepherd, J; Warwick, GL, 1990) |
| "Hyperlipidemia is of particular concern in dialysis patients due to the high incidence of ischemic cardiovascular complications." | ( Heintz, B; Kirsten, R; Nelson, K; Oremek, G, 1989) |
| "Hyperlipidemia is an identified risk factor for atherosclerosis in patients following renal transplantation that may be related to previous uremia and various drugs including steroids." | ( Clark, WF; Holub, BJ; Jevnikar, AM; Petric, R; Philbrick, DJ, 1988) |
| "Hyperlipidemia is common after renal transplantation and has been attributed, at least in part, to corticosteroid therapy." | ( Brunner, FP; Hodel, K; Mordasini, RC; Thiel, G, 1986) |
| "Hyperlipemia is a common manifestation of the nephrotic syndrome." | ( Felts, J; Gambertoglio, J; Hutchison, FN; Kaysen, GA, 1987) |
| "Although hyperlipidemia is a common feature of the nephrotic syndrome, the distribution of cholesterol among the plasma lipoproteins and the mechanism of the enhanced hepatic synthesis of lipoprotein lipids are not well understood." | ( Appel, AS; Appel, GB; Blum, CB; Chien, S; Kunis, CL, 1985) |
| "Hyperlipidemia is common in patients with renal disease." | ( Cramp, DG, 1982) |
| "This hyperlipidemia is due to a selective increase in LDL and HDL concentrations." | ( Baggio, G; Baiocchi, MR; Baldo, G; Crepaldi, G; Fabiani, F; Fellin, R; Manzato, E; Ongaro, G; Pauluzzi, S, 1983) |
| "Many patients with hyperlipidemia are without symptoms, thus laboratory data are often the sole index of therapeutic success or failure." | ( Wilson, DE, 1981) |
| "This dyslipidemia is characterized by a hypertriglyceridemia and reduced levels of HDL-(high density lipoprotein)cholesterol in plasma." | ( Krone, W; Müller-Wieland, D, 1995) |
| "Several forms of dyslipidemia are associated with premature coronary artery disease (CAD) and other vascular disease." | ( Gotto, AM; Yeshurun, D, 1995) |
| "Hyperlipidemia is a significant risk factor for atherosclerotic vascular disease." | ( al'Halawani, MH; Frisbie, K; Larsen, JL; Miller, S; Stratta, RJ; Taylor, RJ, 1994) |
| "Hyperlipemia is an important etiologic factor in the pathogenesis of coronary artery disease." | ( Jacobs, RH; Lal, SM; Nolph, KD, 1993) |
| "Hyperlipidemia is common in renal allograft recipients." | ( Amann, FW; Binswanger, U; Bleisch, JA; Drexel, H; Kuster, GM; Pei, P; Rentsch, K, 1994) |
| "Hyperlipidemia is an important characteristic of nephrotic syndrome (NS)." | ( Chan, JC; Salcedo, JR; Thabet, MA, 1993) |
| "Hyperlipidemia is a common side-effect of oral retinoid treatment, which sometimes interferes with long-term therapy." | ( Lindholm, A; Olsson, AG; Vahlquist, A; Vahlquist, C, 1995) |
| "Hyperlipidemia is the most prevalent coronary risk factor in Austria." | ( Kunze, M; Schwarz, B, 1994) |
| "Dyslipidemia is one of the risk factors for the development of coronary atherosclerosis." | ( Rembold, CM, 1996) |
| "Hyperlipidemia is not only a prominent complication of nephrotic syndrome, but it may also contribute to the further non-immunologic damage of glomeruli." | ( Poledne, R; Stejskalová, A; Stípek, S; Tĕmínová, J; Tesar, V; Zima, T, 1995) |
| "Hyperlipidemia is common after renal transplantation." | ( Kasiske, BL; Massy, ZA, 1996) |
| "Hyperlipidemia is a known cause for acute pancreatitis." | ( Farfel, Z; Gurevitz, O; Mayan, H; Mouallem, M, 1996) |
| "Hyperlipidemia is a probable risk factor for coronary artery disease in this kind of patient." | ( Anguita Sánchez, M; Blanco Cerrada, J; Casares Mediavilla, J; Jiménez Perepérez, JA; López Miranda, J; Muñoz Carvajal, I; Pérez Jiménez, F; Vallés Belsúe, F; Zambrana García, JL, 1996) |
| "Treatment of hyperlipidemia is addressed within the context of overall cardiovascular disease risk but also for stroke prevention." | ( Berglund, LF; Feinberg, W; Goldstone, J; Gorelick, PB; Schneck, M, 1997) |
| "Hyperlipidemia is common in transplant patients." | ( Berenguer, J; Berenguer, M; Bretó, M; Carrasco, D; de Juan, M; Gisbert, C; Mir, J; Prieto, M, 1997) |
| "Hyperlipidemia is an established risk factor for progressive renal damage and proteinuria." | ( Fong, RL; Laguer, MR; Vadgama, JV; Ward, HJ, 1998) |
| "Hyperlipidemia is a hallmark of nephrotic syndrome that has been associated with increased risk for ischemic heart disease as well as a loss of renal function in these patients." | ( Barrett, HA; de Sain-van der Velden, MG; Gadellaa, MM; Kaysen, GA; Rabelink, TJ; Reijngoud, DJ; Stellaard, F; Voorbij, HA, 1998) |
| "Hyperlipidemia is a common feature after organ transplantation." | ( Aranda, JL; de la Calle, A; del Palacio, A; Fernández-Miranda, C; Gómez-Izquierdo, T; Gómez-Sanz, R; Guijarro, C; Larumbe, S; Morales, JM; Moreno, E; Rodicio, JL, 1998) |
| "The primary dyslipidemias are associated with an increased incidence of atherosclerotic vascular disease in coronary, cerebral, and peripheral vessels." | ( Marks, AD, 1998) |
| "Hyperlipidemia is associated with impairment of endothelial function, loss of endothelium dependent vasodilatation, development of inflammatory responses and impairment of anticoagulant function." | ( Idzior-Waluś, B, 1998) |
| "Hyperlipidemia is recognized as one of the major risk factors for the development of coronary artery disease and progression of atherosclerotic lesions." | ( Davignon, J; Farnier, M, 1998) |
| "Hyperlipidemia is a widely acknowledged side effect of thiazide diuretic therapy, but it is often dismissed as a short-term effect of high-dose therapy." | ( Ames, R, 1998) |
| "Although hyperlipidemia is a known risk factor for coronary artery disease, lipid-lowering agents were not used widely until recently because evidence was lacking that they could prolong life." | ( Pedersen, TR, 1998) |
| "Hyperlipidemia is a primary risk factor for coronary artery disease leading to hypertension and ischemic heart disease, for which nifedipine, a calcium channel blocker, is used." | ( Eliot, LA; Foster, RT; Jamali, F, 1999) |
| "Dyslipidemia is believed to be a major source of this increased risk." | ( Haffner, SM, 1999) |
| "Smoking and dyslipidemia are more potent risk factors for nonfatal MI in males who have the -344C allele of CYP11B2." | ( Hautanen, A; Kayes, KM; Kupari, M; Manninen, V; Mänttäri, M; Rosenfeld, S; Tenkanen, L; Toivanen, P; White, PC, 1999) |
| "Diabetic dyslipidemia is a major factor contributing to the accelerated atherosclerosis in type 2 diabetes mellitus." | ( Chan, L; Forte, TM; Ishida, BY; Kobayashi, K; Oka, K; Taniguchi, S, 2000) |
| "Hyperlipidemia is an important cardiovascular risk factor." | ( Hannak, M; Lüscher, TF; Noll, G; Spieker, LE, 2000) |
| "Combined hyperlipemia is a common lipid abnormality associated with coronary heart disease (CHD)." | ( Bønaa, KH; Hansen, JB; Nilsen, H; Nordøy, A; Sandset, PM, 2000) |
| "Mixed hyperlipidemia is characterized by both elevated total cholesterol and triglycerides." | ( Bays, H; Davidson, M; Dujovne, C; Korenman, S; Mercuri, M; Plotkin, D; Stein, E; Stepanavage, M, 2000) |
| "Hyperlipidemia is common in type 2 diabetic patients and is an independent risk factor for cardiovascular disease." | ( Aguilar-Salinas, CA; Alvarado Vega, A; Angélica Gómez-Díaz, R; Eduardo Romero-Nava, L; Gómez-Pérez, FJ; Guillén, LE; Gulías-Herrero, A; Meaney, E; Mendoza Pérez, E; Moguel, R; Novoa, G; Posadas-Romero, C; Salinas-Orozco, S; Vázquez-Chávez, C, 2000) |
| "Dyslipidemia is highly prevalent in the urban areas of Thailand but information in the rural area, particularly in the elderly, is limited." | ( Amornrat, A; Assantachai, P; Yamwong, P, 2000) |
| "Postprandial hyperlipidemia is frequently accompanied with intra-abdominal visceral accumulation in human subjects." | ( Bujo, H; Hikita, M; Kobayashi, J; Saito, Y; Taira, K; Takahashi, K; Yamazaki, K, 2000) |
| "Hyperlipidemia is a risk factor for the progression of coronary artery disease, and possibly also valvular aortic stenosis." | ( Griffin, BP; Novaro, GM; Pearce, GL; Sprecher, DL, 2001) |
| "Dyslipidemia is an important risk factor for cardiovascular complications in diabetes." | ( Banga, JD; Erkelens, DW; Niemeijer-Kanters, SD, 2001) |
| "Mixed hyperlipidemia is a common risk factor for cardiovascular disease." | ( Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L, 2001) |
| "Hyperlipidemia is common after cardiac transplantation and it is a risk factor for post-transplantation coronary artery disease." | ( Fricker, FJ; Harker, K; Kahler, DA; Penson, MG; Schowengerdt, KO; Thompson, JR; Williams, BJ, 2001) |
| "Hypertension and hyperlipidemia are more prevalent after liver transplantation with cyclosporine as the primary immunosuppressive agent compared with tacrolimus." | ( Alexander, GJ; Gibbs, P; Gimson, AE; Neal, DA, 2001) |
| "Hyperlipidemia is observed in the absence of lipodystrophy and depends on PI exposure." | ( Jais, JP; Jubault, V; Médioni, J; Rabian, C; Rakotoambinina, B; Viard, JP, 2001) |
| "Dyslipidemia is an independent factor affecting atherosclerotic arterial wall changes and cardiovascular events in ESRD." | ( Inaba, M; Ishimura, E; Morii, H; Nishizawa, Y; Shoji, T, 2001) |
| "Uremic dyslipidemia is characterized by increased plasma triglycerides due to elevated very low density lipoprotein (VLDL) and decreased high-density lipoprotein (HDL)." | ( Inaba, M; Ishimura, E; Nishizawa, Y; Shoji, T; Tabata, T, 2001) |
| "Hyperlipidemia is frequently developed following renal transplantation and results in worsening of the patient's prognosis." | ( Hatori, M; Ichimaru, N; Inoue, T; Kameoka, H; Kokado, Y; Okuyama, A; Takahara, S; Wang, JD, 2001) |
| "Diabetic dyslipidemia is featured by hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol levels, and elevated low-density lipoprotein (LDL) cholesterol commonly in the form of small, dense LDL particles." | ( Adeli, K; Cheung, RC; Parris, W; Pontrelli, L, 2002) |
| "Hyperlipidemia is now established as a major risk factor for causation of coronary heart disease (CHD) in adults; however, there is much debate on the level of coronary risk at which lipid-lowering drugs should be used." | ( Bhatnagar, D, 2002) |
| "In conclusion, hyperlipidemia is common during the treatment of HIV with protease inhibitors, and fenofibrate appears to be an effective and safe choice for its treatment." | ( Caramelli, B; de Bernoche, CY; Monachini, MC; Santos, RD; Sartori, AM; Sposito, AC; Strabelli, T; Uip, D, 2001) |
| "Hyperlipidemia is an important complication after organ transplantation and contributes to the development of posttransplant accelerated coronary artery diseases." | ( Akhlaghi, F; Jackson, CH; Parameshwar, J; Sharples, LD; Trull, AK, 2002) |
| "Posttransplant hyperlipidemia is a common complication which may affect long term cardiovascular mortality." | ( Akkaya, V; Aras, U; Sever, MS; Tükek, T; Türk, S; Türkmen, A; Uras, AR; Yildiz, A, 2001) |
| "Post-transplant dyslipidemia is determined by genetic and environmental factors." | ( Aguilar-Salinas, CA; Alberú, J; Arellano, A; Correa-Rotter, R; Díaz-Polanco, A; Gómez Pérez, FJ; Macias, N; Ordóñez, ML; Quintana, E; Ramírez, E; Velásquez-Alva, C, 2002) |
| "Diabetic dyslipidemia is characterized by high triglyceride levels; low high-density lipoprotein cholesterol levels; small, dense low-density lipoprotein particles; and high free fatty acid levels." | ( Buse, JB; Fitz-Patrick, D; Ganda, OP; Grundy, SM; Kendall, DM; McGovern, ME; Robertson, DD; Rosenson, RS; Sheehan, JP; Tulloch, BR; Vega, GL, 2002) |
| "Dyslipidemia is also commonly associated with hypertension, hyperinsulinemia and central obesity in the metabolic syndrome." | ( Nordøy, A, 2002) |
| "The dyslipidemia is unique in that very low levels of HDL-C and typically "normal" LDL-C levels characterize the Turkish population." | ( Bersot, TP; Mahley, RW; Palaoğlu, KE, 2002) |
| "Hyperlipidemia is commonly ascribed to obesity." | ( Athiko, D; Khanna, N; Misra, A; Pandey, RM; Sharma, R, 2002) |
| "Hyperlipidemia is a common problem and Atorvastatin is a safe and effective treatment in pediatric renal transplant recipients." | ( Aitken, M; Argent, E; Kainer, G; Mackie, FE; Rosenberg, AR, 2003) |
| "Hyperlipidemia is commonly observed in patients with type 2 diabetes and is also characteristic of the metabolic syndrome." | ( Aikawa, K; Kahn, SE; Knopp, RH; Retzlaff, B, 2003) |
| "Hyperlipidemia is a significant side effect of sirolimus treatment and often leads to vascular disease." | ( Abdel-Fattah, G; Kahan, BD; Morrisett, JD, 2003) |
| "Control of hyperlipidemia is vital in patients with cardiovascular disease (CVD)." | ( Eshraghian, M; Jallali, M; Keshavarz, A; Miri, R; Shidfar, F, 2003) |
| "Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism." | ( Cottrell, DA; Falko, JM; Marshall, BJ, 2003) |
| "Hyperlipidemia is a common problem in solid organ transplant recipients." | ( Arbeiter, K; Aufricht, C; Balzar, E; Koeppe, S; Luckner, D; Müller, T; Salzer, U, 2003) |
| "Hyperlipidemia is associated with endothelial dysfunction, an early event in atherosclerosis and predictor of risk for future coronary artery disease." | ( Chiu, EY; Cooke, JP; Engler, MB; Engler, MM; Lin, KY; Malloy, MJ; Mietus-Snyder, M; Miller, E; Morrow, JD; Paul, SM; Ridker, PM; Rifai, N; Schloetter, MC; Stuehlinger, M; Witztum, JL, 2003) |
| "Dyslipidemia is one of the most important modifiable risk factors for coronary disease." | ( Miller, M, 2003) |
| "Hyperlipidemia is one of the main risk factors of cardiovascular complications in diabetes." | ( Atabak, S; Azadbakht, L; Esmaill-Zadeh, A; Jamshidian, M; Mehrabi, Y; Shakerhosseini, R, 2003) |
| "Dyslipidemia is associated with macular exudates and vision loss." | ( Fong, D; Jain, A; Sarraf, D, 2003) |
| "Hyperlipidemia is a secondary disorder associated with many metabolic disorders including hypothyroidism." | ( Abdel-Gayoum, AA; Al-Tonsi, AA; Saad, M, 2004) |
| "Hyperlipidemia is a common and important risk factor after renal transplantation, but there is little long-term data on its incidence, pattern, and evolution in stable renal allograft recipients on low dose maintenance immunosuppression." | ( Chan, TM; Lai, KN; Lam, MF; Li, FK; Tse, KC; Yip, PS, 2004) |
| "Diabetes-induced dyslipidemia is seen in streptozotocin-induced diabetic rats." | ( Furukawa, K; Hakamata, H; Hori, M; Horiuchi, S; Komohara, Y; Miyazaki, A; Sakamoto, Y; Sasaki, Y; Satoh, M; Takeya, M, 2004) |
| "Primary hyperlipidemia is caused by various molecular defects in lipid metabolism." | ( Bujo, H; Gotoda, T; Ishibashi, S; Kita, T; Maruyama, T; Matsuzawa, Y; Ohashi, K; Saito, Y; Shionoiri, F; Takahashi, K; Yamada, N; Yamashita, S, 2004) |
| "Postprandial lipemia is markedly modulated when carbohydrates are added to a fatty meal." | ( Dierkes, J; Kästner, S; Leodolter, A; Luley, C; Taneva, E; Westphal, S, 2004) |
| "Postprandial lipemia is also moderately reduced." | ( Dierkes, J; Kästner, S; Leodolter, A; Luley, C; Taneva, E; Westphal, S, 2004) |
| "Dyslipidemia is a heterogeneous metabolic condition; high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very-low-density lipoprotein represent families of lipoprotein particles that differ in size and composition and vary in atherogenicity." | ( Capuzzi, DM; Carey, CM; Lincoff, A; Morgan, JM, 2004) |
| "Dyslipidemia is common among patients receiving antiretroviral therapy for HIV infection." | ( Bellehumeur, JB; McBride, PE; Merwood, MA; Sosman, JM; Stein, JH; Wiebe, DA, 2005) |
| "Dyslipidemia is an increasing problem in most industrialized societies and is a risk factor for coronary heart disease (CHD)." | ( Casey, DE, 2004) |
| "Atherogenic dyslipidemia is an important factor in cardiovascular risk in these patients, and treatment of atherogenic dyslipidemia has been identified as an important goal of therapy in patients with MS." | ( Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH, 2005) |
| "Hyperlipidemia is an associated complication of diabetes mellitus." | ( Amarnath Satheesh, M; Pari, L, 2004) |
| "Dyslipidemia is frequent in patients with renal failure and in transplant recipient patients." | ( Deray, G; Izzedine, H; Launay-Vacher, V, 2005) |
| "Hyperlipidemia is an important risk factor for atherosclerosis." | ( Alacacioglu, A; Caliskan, S; Ceylan, C; Comlekci, A; Saklamaz, A; Temiz, A; Yesil, S, 2005) |
| "Hyperlipidemia is a common problem among heart transplant recipients." | ( Burton, I; Koshman, SL; Lalonde, LD; Pearson, GJ; Tymchak, WJ, 2005) |
| "Hyperlipidemia is frequently developed following renal transplantation and results in worsening of the patient's prognosis." | ( Ichimaru, N; Imamura, R; Matsumiya, K; Moriyama, T; Namba, Y; Nonomura, N; Okuyama, A; Shi, Y; Takahara, S; Toki, K, 2005) |
| "Dyslipidemia is highly prevalent in many patients who receive a boosted PI regimen." | ( Cohen, CJ, 2005) |
| "Now hyperlipidemia is treated frequently with HMG-CoA reductase inhibitor, but there are few reports demonstrating lung injury by this drug." | ( Hisatomi, K; Ide, M; Ishii, H; Ishimoto, H; Kakugawa, T; Kohno, S; Mukae, H; Nakayama, S; Sugiyama, K; Yoshioka, S, 2005) |
| "Dyslipidemia is one of the main risk factors for atherosclerosis, usually the underlying cause of cardiovascular diseases which are the major cause of morbidity and mortality in developed countries." | ( Accinni, R; Bamonti, F; Bernacchi, F; Campolo, J; Caruso, R; Ciani, A; Della Noce, C; Ghersi, L; Gorini, M; Grossi, S; Ippolito, S; Lonati, S; Lorenzano, E; Novembrino, C; Rosina, M; Tonini, A, 2006) |
| "Hyperlipidemia is common in pediatric thoracic transplant patients and persists over time." | ( Agatisa, P; Boyle, GJ; Law, YM; Lawrence, K; Miller, SA; Webber, SA; Yim, R, 2006) |
| "Combined hyperlipidemia is associated with endothelial dysfunction." | ( Borucki, K; Luley, C; Makarova, R; Schmidt-Lucke, C; Taneva, E; Westphal, S; Wiens, L, 2006) |
| "Hyperlipidemia is a frequent complication after renal transplantation." | ( Bora, S; Gülay, H; Kasap, B; Kavukçu, S; Soylu, A; Türkmen, MA, 2006) |
| "Hyperlipidemia is one of the major risk factors of cardiovascular complication in diabetes." | ( Arsić, A; Blazencić Mladenović, V; Postić, M; Ristić Medić, D; Ristić, G; Ristić, V; Tepsić, J, 2006) |
| "Lipemia is an uncommon adverse effect of propofol infusion." | ( Armstrong, WB; Linskey, ME; Vokes, DE, 2006) |
| "Lipemia is an uncommon adverse effect of propofol infusion, which may give blood a milky appearance and be confused for a chyle leak in a dissected neck." | ( Armstrong, WB; Linskey, ME; Vokes, DE, 2006) |
| "Chemokines and hyperlipidemia are involved in the mechanism of chronic allograft nephropathy (CAN)." | ( Li, Q; Wang, D; Wang, Y; Xu, Q, 2006) |
| "Hyperlipidemia is a recognized complication of HIV antiretroviral therapy." | ( Angel, JB; Cooper, CL; Mills, E, 2007) |
| "Hyperlipidemia is commonly observed in patients with type 2 diabetes and is an independent risk factor for cardiovascular disease." | ( Moulik, N; Patil, N; Rajadhyaksha, G; Save, V, 2006) |
| "Mixed hyperlipidemia is characterized by elevated low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), and TG-rich lipoprotein levels." | ( Davies, MJ; Farnier, M; Gil-Extremera, B; Hamlin, C; Kush, D; Macdonell, G; Mendez, GF; Mitchel, YB; Perevozskaya, I; Roth, E, 2007) |
| "Mixed hyperlipidemia is a major cause of coronary artery disease." | ( Badyal, DK; Calton, R; Chatley, P; Khosla, PP, 2007) |
| "The incidence of dyslipidemia is not different between people of middle age and old age." | ( Kozaki, K, 2007) |
| "Hyperlipidemia is a metabolic complication after liver transplantation (LT)." | ( Bordbar, MR; Dehghani, SM; Eshraghian, A; Gholami, S; Imanieh, MH; Malek-Hosseini, SA; Taghavi, SA, 2007) |
| "Hyperlipidemia is less pronounced in patients given tacrolimus." | ( Kostakis, A; Moulakakis, KG; Nikiteas, N; Perrea, DN; Poulakou, MV; Vlachos, IS, 2008) |
| "Hyperlipidemia is a powerful risk factor of atherosclerosis." | ( Ceska, R; Chytilová, E; Lacinová, Z; Malík, J; Marek, J; Melenovský, V; Stulc, T; Wichterle, D, 2008) |
| "Nephrotic dyslipidemia is a risk factor for the development of systemic atherosclerosis; it may also aggravate glomerulosclerosis and enhance the progression of glomerular disease." | ( Abdelsalam, M; Gheith, O; Sheashaa, H; Shoeir, Z; Sobh, M, 2008) |
| "Fifth, combined hyperlipidemia is the most common lipid disorder, has the strongest risk for CVD, and combines elevated LDL, hypertriglyceridemia, and low HDL." | ( Atkinson, B; Dowdy, A; Knopp, RH; Paramsothy, P, 2008) |
| "Hyperlipidemia is the major risk factors of heart disease such as atherosclerosis, stroke, and death." | ( Jang, A; Jo, C; Lee, JW; Lee, M; Lee, NY; Song, HP; Srinivasan, P, 2008) |
| "Hyperlipidemia is common in patients after LTX." | ( Aufricht, C; Becker, J; Huber, WD, 2008) |
| "Hyperlipidemia is one of the vital coronary risk factors and is positively related to morbidity and mortality of coronary heart disease." | ( Du, J; Jia, M; Qin, LP; Wu, JZ; Xing, WW; Zhang, H, 2009) |
| "Obesity and hyperlipidemia are common findings after kidney transplantation (Tx), and may represent independent risk factors for development of atherosclerosis and chronic allograft nephropathy." | ( Schück, O; Stollova, M; Teplan, V; Vitko, S, 2007) |
| "Postprandial lipemia is known to exert a reversible detrimental effect on endothelium-dependent flow-mediated vasodilation (FMD)." | ( Abletshauser, C; Luley, C; Westphal, S, 2009) |
| "Dyslipidemia is an important complication affecting kidney transplant recipients." | ( Anaya, F; Rodríguez-Ferrero, ML, 2008) |
| "Hyperlipidemia is common in dogs, and can be either primary or secondary to other diseases." | ( Steiner, JM; Xenoulis, PG, 2010) |
| "Hyperlipidemia is a major risk factor for cardiovascular disease." | ( Aykaç, Y; Bozkurt, FY; Fentoğlu, O; Oz, G; Taşdelen, P; Uskun, E, 2009) |
| "Dyslipidemia is common in nephrotic children and persistent lipid abnormalities are risk factor of late vascular complications." | ( Grenda, R; Ksiazek, J; Lipka, M; Niemirska, A; Syczewska, M; Wierzbicka, A, 2009) |
| "Nephrotic dyslipidemia is a risk factor for development of systemic atherosclerosis; also it may aggravate glomerulosclerosis and enhance progression of glomerular disease." | ( Abdelsalam, M; Gheith, O; Sheashaa, H; Shoeir, Z; Sobh, M, 2009) |
| "Hyperlipidemia is a risk factor for the development of coronary heart disease." | ( McGowan, MP; Proulx, S, 2009) |
| "Hyperlipidemia is found to be associated with changes in fatty acid (FA) profiles." | ( Glibetic, M; Ristic-Medic, D; Suzic, S; Takic, M; Tepsic, J; Vucic, V, 2009) |
| "Hyperlipidemia is a risk factor for development and progression of diabetic nephropathy." | ( Brandewie, K; Mitchell, B; Schaefer, L; Taneja, D; Tannock, LR; Thompson, J; Wilson, P, 2010) |
| "Hyperlipidemia is associated with abnormalities in both the nerves and endothelium." | ( Fandel, TM; Harraz, AM; Huang, YC; Lin, CS; Lin, G; Lue, TF; Ning, H; Shindel, AW, 2010) |
| "Hyperlipidemia is a major cause of atherosclerosis and atherosclerosis-associated conditions in cardiovascular diseases." | ( Gong, G; Huang, W; Li, D; Qin, Y; Wu, X; Yang, X; Zhao, Y; Zhou, S, 2010) |
| "Obesity and hyperlipidemia are associated with impaired insulin sensitivity in human type 2 diabetes mellitus, possibly due to activation of a mild inflammatory response." | ( Ackermann, M; Franchini, M; Guscetti, F; Kaufmann, K; Konrad, D; Lutz, TA; Osto, M; Reusch, CE; Sieber-Ruckstuhl, NS; Zini, E, 2010) |
| "Hypertension and dyslipidemia are highly co-prevalent, but often poorly controlled, coronary heart disease (CHD) risk factors." | ( Chen, L; Eaddy, M; Jackson, JH; Kean, AJ; Lunacsek, OE; Neutel, JM; Roberts, C, 2010) |
| "Patients with dyslipidemia are shown to benefit largely from the modification of Lp-PLA2." | ( Arora, R; Racherla, S, 2012) |
| "Hyperlipidemia is a major risk factor for cardiovascular diseases." | ( Gao, J; Guo, P; Kai, Q; Lian, ZQ; Wu, CA; Wu, CM; Zhu, HB, 2010) |
| "Hyperlipidemia is a common feature of type 2 diabetes and is related to cardiovascular disease." | ( Cianflone, K; Liu, Y; Sun, T; Wang, DW; Xu, Y; Yang, Y; Yuan, G; Zhang, J; Zhang, M, 2011) |
| "Hyperlipidemia is a major risk factor for development of coronary artery disease." | ( Muthukumar, K; Nachiappan, V; Sabarirajan, J; Vijayaraj, PS, 2011) |
| "Hyperlipidemia is a common metabolic disorder contributing to morbidities and mortalities due to cardiovascular and cerebrovascular diseases." | ( Abasi, B; Hashem Dabaghian, F; Kianbakht, S; Perham, M, 2011) |
| "Postprandial hyperlipemia is closely correlated with transient endothelial dysfunction." | ( Enko, K; Ito, H; Kohno, K; Kusano, KF; Miyoshi, T; Morita, H; Nakamura, K; Yunoki, K, 2011) |
| "Diabetic dyslipidemia is suggested to be an additional important contributor to CVD risk in T2DM." | ( Ansar, S; Koska, J; Reaven, PD, 2011) |
| "Hyperlipidemia is a highly prevalent risk factor for ischemic stroke." | ( Doeppner, TR; ElAli, A; Hermann, DM; Zechariah, A, 2011) |
| "Hyperlipidemia is considered one of the key factors for cardiovascular diseases." | ( Brahmkshatriya, PS; Chhabria, MT; Raval, PM; Suhagia, BN, 2011) |
| "Dyslipidemia is observed among older children and adults with HIV." | ( Cohen, RA; Gonin, R; Hazra, R; Hofer, CB; Monteiro, JP; Negra, MD; Ruz, NP, 2012) |
| "Hyperlipidemia is common after kidney transplantation, especially in the first year after transplantation." | ( Behzadi, S; Eshraghian, A; Eshraghian, H; Faghihi, A; Raees-Jalali, G; Roozbeh, J; Sagheb, MM, 2012) |
| "Dyslipidemia is a modifiable risk factor that should be treated early for CVD prevention." | ( Rudkowska, I, 2012) |
| "Hyperlipidemia is a potentially modifiable risk factor for cardiovascular morbidity." | ( Casier, S; Filler, G; Gharib, MT; Weiglein, G, 2012) |
| "Hyperlipidemia is associated with an increased risk of erectile dysfunction." | ( Lee, JH; Lee, YJ; Oh, JH, 2012) |
| "Dyslipidemia is a frequent component of the metabolic disorder of diabetic patients contributing to organ damage." | ( Bonrouhi, M; Gretz, N; Gröne, E; Gröne, HJ; Kiss, E; Kränzlin, B; Malle, E; Nordström, V; Teupser, D; Thiery, J; Wagenblaβ, K, 2013) |
| "As postprandial lipemia is closely correlated to cardiovascular disease, long-term dietary supplementation with whey protein may prove beneficial in preventing cardiovascular disease in obese non-diabetic subjects." | ( Astrup, A; de Vrese, M; Hermansen, K; Holmer-Jensen, J; Holst, JJ; Mortensen, LS; Thomsen, C, 2013) |
| "The hyperlipidemia is also reversible in nature." | ( Brocks, DR; Chaudhary, HR, 2013) |
| "Hyperlipidemia is associated with an increased risk of cardiovascular events; reducing low-density lipoprotein cholesterol (LDL-C), the primary target for cholesterol-lowering therapy, lowers the risk for such events." | ( Jones, MR; Nwose, OM, 2013) |
| "Hyperlipidemia is an associated complication of diabetes and also a major risk factor for cardiovascular diseases." | ( Ramachandran, V; Saravanan, R; Senthilraja, P, 2014) |
| "Hyperlipidemia is referred to as hypercholesterolemia, hypertriglyceridemia, or both in combined hyperlipidemia." | ( Jia, ZH; Ko, KM; Pan, SY; Sun, N; Wang, XY; Yu, Q; Yu, ZL; Zhang, Y; Zhu, PL, 2013) |
| "Hyperlipidemia is a major cardiovascular risk factor associated with progressive cerebrovascular dysfunction and diminished collateral perfusion in stroke." | ( Ayata, C; Huang, PL; Shin, HK, 2014) |
| "Hyperlipidemia is an independent risk factor in the development of ischemic heart disease, which can increase myocardial susceptibility to ischemia/reperfusion (I/R) injury." | ( Li, X; Liu, H; Wang, J; Wu, Y; Zhang, S; Zhang, Y; Zhao, H; Zhao, X, 2014) |
| "Hyperlipidemia is one of the major risk factor for the development of cardiovascular disease." | ( Chen, G; Wang, H; Yang, ST; Zhang, X, 2014) |
| "Hyperlipidemia is a well-recognized risk factor for atherosclerosis and can be regulated by adipokines." | ( Choi, HS; Choi, JH; Jeon, S; Jeong, SJ; Jeong, TS; Jeong, W; Jung, IH; Kim, HC; Kim, JB; Lee, M; Lee, MN; Lee, MR; Lee, YH; Lim, CJ; Oh, GT; Oh, KS; Park, JG; Sonn, SK; Yang, Y; Yoon, WK, 2014) |
| "Hyperlipidemia is a major, modifiable risk factor for atherosclerosis and cardiovascular disease." | ( Chandrasekaran, B; Jayachandran, M; Namasivayam, N, 2015) |
| "Hyperlipidemia is one of the most important risk factors of ischemic heart disease." | ( Entezari, MH; Siavash, M; Torkan, M, 2015) |
| "Hyperlipidemia is known to be a major risk factor for the development of cardiovascular diseases (CVDs) which include atherosclerosis, coronary heart disease, and stroke." | ( Adeghate, E; Dhas Devavaram, J; Dhas, J; Reddy, MM; Starling Emerald, B, 2015) |
| "Hyperlipidemia is a disease with abnormally elevated levels of lipids/lipoproteins in the blood, and it is regarded as an important risk factor for cardiovascular and cerebrovascular diseases." | ( Jia, BB; Lv, YD; Mao, GX; Wang, GF; Wang, YZ; Yang, ZX; Yu, H, 2016) |
| "Hyperlipidemia is a major risk factor for incidence of coronary artery disease." | ( Majeed, A; Muneera, KE; Naveed, AK, 2015) |
| "Hyperlipidemia is regarded as independent risk factor in the development of ischemic heart disease, and it can increase the myocardial susceptibility to ischemia-/reperfusion (I/R)-induced injury." | ( Deshmukh, R; Goyal, S; Jyoti, U; Kansal, SK; Kaura, A; Sharma, S, 2015) |
| "Hyperlipidemia is not unusual in liver transplant recipients, but refractory severe hyperlipidemia is unusual." | ( Liu, ZW; Luo, XB; Min, Z; Su, HB; Sun, YL; Xia, Z, 2015) |
| "Hyperlipidemia is common among RA patients and is significantly associated with CRP levels and disease activity." | ( Attar, SM, 2015) |
| "Although hyperlipidemia is a well known adverse event of atypical antipsychotic (AAP) medication, there are few studies that have quantitatively compared the risks of various AAPs." | ( Ishiguro, C; Kajiyama, K; Takeuchi, Y; Uyama, Y, 2015) |
| "Both diabetes and hyperlipidemia are thought to increase these risk factors and therefore potentially enhance RCD development." | ( Chang, CL; Chang, ST; Chi, CH; Lin, CH; Lin, TT; Sheu, WH, 2015) |
| "Dyslipidemia is an established risk factor for ischemic heart disease." | ( Asgary, S; Goli-Malekabadi, N; Sahebkar, A, 2015) |
| "Hyperlipidemia is a major factor causing coronary heart disease and atherosclerosis." | ( Chen, SH; Li, B; Lv, GY; Pan, DD; Tang, QJ, 2015) |
| "Hypertension and hyperlipidemia are major cardiovascular disease risk factors." | ( Acharya, SD; Braun, LT; Finnie, RK; Goetzel, RZ; Hopkins, DP; Jacob, V; Kottke, TE; Lackland, DT; Njie, GJ; Proia, KK; Pronk, NP; Rask, KJ, 2015) |
| "Postprandial hyperlipidemia is a condition in which TG-rich chylomicron remnants are increased during the postprandial period and hypertriglycedemia is protracted." | ( Ito, H; Miyoshi, T; Nakamura, K; Yunoki, K, 2016) |
| "Hyperlipidemia is a major cause of atherosclerotic cardiovascular disease." | ( Chen, H; Hatami, L; Khazaeli, M; Miao, H; Tang, DD; Tarbiat-Boldaji, M; Vaziri, ND; Zhao, YH; Zhao, YY, 2016) |
| "Moreover, hyperlipidemia is known to impair the endothelial function by causing oxidative stress." | ( Cao, ZP; Li, CH; Wei, PJ; Wu, ML; Xiao, P; Zhuang, SY, 2016) |
| "Hypertension and hyperlipidemia are important risk factors for CVD that are modifiable by pharmacological treatment and life-style changes." | ( Cook, S; Cybulsky, M; Kontsevaya, AV; Leon, DA; Vasiljev, M, 2016) |
| "Hyperlipidemia is a lipid metabolism disorder and the major risk factor for the development of CVDs." | ( Abid, R; Mahmood, R; Santosh Kumar, HS, 2016) |
| "Hyperlipidemia is a major risk factor for cardiovascular diseases." | ( Akhondi, N; Fallah, S; Jamshidi, S; Sayar, F, 2016) |
| "Hyperlipidemia is a major component of metabolic syndrome, and often predicts cardiovascular diseases." | ( Ji, G; Li, M; Shu, X; Xu, H; Yang, L; Zhang, C; Zhang, L, 2016) |
| "Dyslipidemia is a major risk factor for the development of cardiovascular diseases." | ( Abu Farha, R; Abu Shiekha, G; Al-Hiari, Y; Al-Qirim, T; Albashiti, R; Bustanji, Y, 2016) |
| "Hyperlipidemia is one of the principal factors underlying numerous metabolic diseases, including diabetes and obesity." | ( Ma, S; She, L; Tian, X; Yan, S; Yang, W; Yu, K; Zhang, X, 2016) |
| "Men with hyperlipidemia are more likely to have erectile dysfunction (ED) than those without hyperlipidemia, but the mechanisms are not fully understood." | ( Cui, K; Li, R; Li, X; Liu, J; Qiu, J; Rao, K; Wang, S; Wang, T; Wen, B; Yu, G, 2017) |
| "Hyperlipidemia is a risk factor for the development of cognitive dysfunction and atherosclerosis." | ( Abdalla, FH; Adefegha, SA; Braun, JBS; Castilhos, LG; da Silva, CB; de Oliveira, JS; Guedes Manzoni, A; Leal, DBR; Lopes, STA; Rubin, MA; Ruchel, JB; Signor, C; Trelles, K, 2017) |
| "Hyperlipidemia is associated with increased risk of atherosclerosis; therefore, control of this risk factor is very important in preventing atherosclerosis." | ( Asghari, G; Farazmand, A; Ghanadian, SM; Hashemi, M; Heshmat-Ghahdarijani, K; Kharazmkia, A; Soltani, R, 2017) |
| "Hyperlipidemia is a risk factor for Alzheimer's disease (AD) and other neurodegenerative diseases." | ( Jiang, ZS; Liu, HT; Liu, LS; Pan, LH; Peng, J; Ren, Z; Tang, ZH; Wang, GX; Wu, Q; Zhao, XS, 2017) |
| "Hyperlipidemia is a group of disorders characterized by excessive lipids in the bloodstream." | ( Adefegha, SA; Braun, JBS; Castilhos, LG; Coelho, APV; de Andrade, CM; Dornelles, GL; Leal, DBR; Oliveira, JS; Rubin, MA; Ruchel, JB; Signor, C; Trelles, KB, 2017) |
| "Hyperlipidemia is a known cause of coronary vascular diseases, which is a major cause of death in many parts of the world." | ( Abu Sheikha, G; Al-Essa, L; Al-Hiari, Y; Al-Qirim, T; Azmy, N; Hamadneh, L; Hikmat, S; Shattat, G, 2017) |
| "Hyperlipidemia is a risk factor for initiation and progression of diabetic nephropathy but the metabolic pathways altered in the diabetic kidney in a context of hyperlipidemia remain incompletely described." | ( Bascands, JL; Denis, C; Gillet, M; Klavins, K; Klein, J; Koal, T; Marsal, D; Mirzoyan, K; Saulnier-Blache, JS; Schanstra, JP, 2017) |
| "Hyperlipidemia is one of the major risk factors for atherosclerosis and ischemic heart disease." | ( Baalash, A; Ebeid, AM; Shafik, NM, 2017) |
| "Hyperlipidemia is characterized by high levels of plasma triglycerides and LDL-cholesterol, accompanied by reduced HDL-cholesterol levels, and is often associated with an increased risk of cardiovascular diseases." | ( Allgayer, MDC; de Barros Falcão Ferraz, A; de Sousa, JA; Marroni, NP; Pereira, P; Picada, JN, 2017) |
| "Hyperlipidemia is a metabolic disorder that is caused by high levels of triglycerides and cholesterol in blood." | ( Ahmad, A; Ahmad, T; Ahmed, Z; Kamal, F; Naz, R; Shahzad, M; Tareen, RB, 2017) |
| "Hyperlipidemia is a chronic disorder which plays an important role in the development of cardiovascular diseases, type 2 diabetes, atherosclerosis, hypertension, and nonalcoholic fatty liver disease." | ( Chen, K; Feng, M; Liang, T; Liu, C; Shao, W; Wu, J; Zhong, H, 2018) |
| "Dyslipidemia is the key precursor of atherosclerotic cardiovascular disease." | ( Abdullah, N; Aminudin, N; Seng, CK, 2017) |
| "Hyperlipidemia is known as an elevation of plasma lipid components." | ( Al-Hiari, Y; Al-Qirim, T; Bkhaitan, MM; Hamadneh, L; Kalloush, H; Khalaf, RA; Sheikha, GA, 2018) |
| "The prevalence of hyperlipidemia is increasing rapidly." | ( Chen, X; Cui, G; Hong, L; Li, A; Li, H; Li, Y; Liu, J; Ren, Z; Song, Y; Sun, J; Sun, R; Wulasihan, M; Yu, Z, 2018) |
| "Hyperlipidemia is a risk factor for various cardiovascular and metabolic disorders." | ( Dong, B; Kou, L; Li, Y; Qin, Q; Song, Y; Yang, J; Yang, N, 2018) |
| "BACKGROUND Hyperlipidemia is a major cause of atherosclerotic cardiovascular disease." | ( Chen, Z; Ding, K; Sun, C; Wang, H, 2018) |
| "Objective- Dyslipidemia is one of the key factors behind coronary heart disease." | ( Gordts, PLSM; Hokkanen, K; Jauhiainen, M; Kaikkonen, MU; Kettunen, S; Laakso, H; Niskanen, H; Ramms, B; Tirronen, A; Vuorio, T; Ylä-Herttuala, S, 2018) |
| "Dyslipidemia is a risk factor for clinically significant thrombotic events." | ( Cameron, SJ; Cooley, BC; Jobe, SM; Kholmukhamedov, A; Morrell, CN; Schulte, ML; Scoggins, NO; Silverstein, RL; Wood, JP; Yang, M, 2018) |
| "Hyperlipidemia is associated with endothelial dysfunction and inflammatory disorders." | ( Bernardes, VM; Bremm, JM; da Silva, JLG; de Andrade, CM; de Oliveira, JS; Jantsch, MH; Leal, DBR; Mann, TR; Manzoni, AG; Passos, DF, 2019) |
| "Postprandial hyperlipidemia is associated with oxidative stress and is an important risk factor for atherosclerosisand cardiovascular disease." | ( AbdulWahab, M; Akpan, JL; Araromi, EJ; Erejuwa, OO; Erhiano, E; Ezeokpo, BC; Nwobodo, NN; Sulaiman, SA; Ude, UN; Uwaezuoke, NJI, 2018) |
| "Hyperlipidemia is a major component of metabolic syndrome, and regarded as one of the main risk factors causing metabolic diseases." | ( Huang, W; Kou, J; Li, F; Yang, X; Yang, Z; Zhou, P, 2019) |
| "Hyperlipidemia is a serious health threat that has been linked to oxidative stress and systemic inflammation, causing among many other disorders essentially liver disease." | ( Chekir-Ghedira, L; Dhaouefi, Z; Ghedira, K; Kalboussi, Z; Khlifi, R; Kilani-Jaziri, S; Lahmar, A; Maatouk, M, 2019) |
| "Dyslipidemia is a primary, critical risk factor for cardiovascular disease." | ( Kang, HT; Kwon, YJ; Lee, JW, 2019) |
| "Dyslipidemia is commonly observed in various kidney diseases, renal specific secreted erythropoietin (EPO) may participate in this process." | ( Ding, H; Du, S; Li, J; Tian, J; Yang, M; Yu, Z, 2019) |
| "Postprandial dyslipidemia is a common feature of insulin-resistant states and contributes to increased cardiovascular disease risk." | ( Adeli, K; Anakk, S; Baker, C; Dean, AE; Farr, S; Hoffman, S; Masoudpoor, H; Stankovic, B; Taher, J, 2020) |
| "Hyperlipidemia is a major risk factor for cardiovascular diseases." | ( Han, L; Li, H; Liu, R; Mushtaq, N; Shi, Y; Ullah, S; Wu, R; Xu, J; Yuan, L; Zhang, J; Zhang, S, 2020) |
| "Hyperlipidemia is considered to be a very dangerous factor leading to cardiovascular and cerebrovascular diseases, especially atherosclerosis." | ( Cui, X; Miao, J; Zang, X; Zhang, J, 2020) |
| "It is known that hyperlipidemia is a risk factor for sensorineural hearing loss." | ( Choo, OS; Choung, YH; Gil, ES; Jang, JH; Kang, Y; Kim, YJ; Lee, YY, 2020) |
| "Hyperlipidemia is closely associated with various liver diseases, and effective intervention for prevention and treatment is in great need." | ( Cao, K; Liu, J; Liu, X; Lv, W; Wang, K; Yang, M, 2020) |
| "Hyperlipidemia is a risk factor for cardiac damage and cardiovascular disease." | ( Dong, M; Guo, Y; Pei, ZW; Wang, F; Zhang, Q; Zhu, HL, 2020) |
| "Hyperlipidemia is also a common disease that is common in modern people, and has a tendency to become younger." | ( Jiang, X; Wang, X; Wu, Z, 2021) |
| "Hyperlipidemia is strongly associated with prevalence of coronary plaques (P < 0." | ( Halabi, M; Hussein, O; Israeli, Z; Regev-Avraham, Z; Rosenfeld, I; Sharabi-Nov, A, 2021) |
| "Hyperlipidemia is a well-established risk factor for cardiovascular diseases." | ( Ahrends, R; Biessen, EAL; Clemetson, KJ; Dubois, LJ; Farndale, RW; Heemskerk, JWM; Kuijpers, MJE; Peng, B; Sickmann, A; Sluimer, JC; Solari, FA; Swieringa, F; Tullemans, BME; van Geffen, JP; van Kuijk, K; Zahedi, RP, 2020) |
| "Hyperlipidemia is the clinical condition where blood has an increased level of lipids, such as cholesterol and triglycerides." | ( Gopalan, RK; Jalaja, R; Leela, SG; Mohan, S; Nair, MS; Somappa, SB, 2021) |
| "Hyperlipidemia is a risk factor for cardiovascular disease, and miR-21a-5p plays an important role in the occurrence and progression of hyperlipidemia." | ( Chen, A; Chen, L; Song, Y; Wang, Y; Wu, B; Yan, F; Zeng, Y; Zhao, J, 2021) |
| "Dyslipidemia is a chronic non-transmissible condition that has increased due to an unhealthy lifestyle." | ( Florean, EOPT; Guedes, MIF; Holanda, MO; Lima, CLS; Lira, SM; Marques, MMM; Mendes, FNP; Moura, LFWG; Oriá, RB; Paim, RTT; Rodrigues, PAS; Silva, BBD; Silva, JYGD; Vieira, IGP, 2021) |
| "Dyslipidemia is a risk factor for the pathogenesis of several diseases, such as obesity, hypertension, atherosclerosis and cardiovascular diseases." | ( Botelho, FV; de Moura, FBR; de Souza, AV; Espindola, FS; Franco, RR; Justino, AB; Ramos, LPA; Saraiva, AL; Silva, HCG; Tavernelli, N, 2021) |
| "Hyperlipidemia is one of the leading causes of, atherosclerosis, and cardiovascular disease." | ( Akhtar, F; Kumar, R; Rizvi, SI, 2021) |
| "Hyperlipidemia is manifested by abnormal levels of circulating lipids and may lead to various cardiovascular diseases." | ( Du, Z; Jia, S; Jiang, H; Li, L; Wang, M; Wang, R; Yan, Y, 2021) |
| "Hyperlipidemia is quite common in IMN." | ( Dong, L; Han, M; Wei, W; Xu, G, 2021) |
| "Hyperlipidemia is a potent risk factor for the development of cardiovascular diseases." | ( Jin, H; Kim, HJ; Ko, YS; Nyandwi, JB; Park, SW; Yun, SP, 2021) |
| "Hyperlipidemia is emerging as an important cause of adverse health outcomes including cardiovascular complications, obesity, metabolic disorders, and infertility." | ( Chukwunweike, C; Ekakitie, MO; Emelike, CU; Fredrick, CC; Nwite, EJ; Okoro, FE, 2021) |
| "Hyperlipidemia is a traditional risk factor for CVD." | ( Alzahrani, KJ; Banu, S; Elfaki, I; Frah, EAM; Mir, MM; Mir, R, 2022) |
| "Hyperlipidemia is intricately associated with the dysregulation of gut microbiota and host metabolomes." | ( Akan, OD; Chen, J; Guo, T; Han, S; Hu, Z; Lin, Q; Luo, F; Qin, D; Wang, J; Yan, S; Zhou, Y; Zhu, L, 2022) |
| "Hyperlipidemia is one of the consequences of type 2 diabetes mellitus (T2DM) that puts the patients at the risk of getting cardiovascular disease." | ( Ahmad Abadi, AN; Dastan, D; Majd, FS; Poorolajal, J; Talebi, SS, 2022) |
| "Individuals with hyperlipidemia are two times more likely to develop atherosclerotic cardiovascular disease (ASCVD) as opposed to those with controlled serum total cholesterol (TC) levels." | ( Aboulwafa, MM; Ali, SM; Salem, FE; Shawky, RM, 2022) |
| "Hyperlipidemia is a serious disorders affecting the metabolism of fats in the human body, and it is usually associated with some serious cardiovascular complications increasing the risk for sudden death." | ( Hasson, TS; Helal, MG; Said, E, 2022) |
| "Dyslipidemia is one of the major public health problems in China." | ( Duan, Q; Hong, N; Huang, Y; Lin, Y; Xie, S; Yang, C; Ye, Z, 2022) |
| "Hyperlipidemia is the primary cause of heart disorders and has been manifested as the condition with remarkable higher levels of very-low-density lipoproteins, low-density lipoproteins, intermediate-density lipoprotein, triglycerides, and cholesterol in blood circulation." | ( Aleya, L; Almoshari, Y; Behl, T; Bungau, S; Kanojia, N; Mohan, S; Salawi, A; Sehgal, A; Sharma, N; Singh, S; Zahoor, I, 2022) |
| "Hyperlipidemia is the systemic manifestation of abnormal lipid metabolism, characterized by elevated circulating levels of cholesterol and triglyceride and a high risk of cardiovascular events." | ( Ge, J; Huang, N; Li, F; Li, X; Liu, R; Sun, R; Wang, D; Zheng, Q, 2023) |
| "Dyslipidemia is one of the modifiable risk factors for cardiovascular disease and a leading cause of morbidity and mortality worldwide." | ( Ali, N; Islam, F; Kathak, RR; Samadder, M, 2023) |
| "Hyperlipidemia is one of the metabolic disorders posing great threat to human health." | ( Ding, H; Hu, Y; Jiang, X; Liu, Q; Lu, Y; Ma, A; Sun, H; Zhang, H, 2023) |
| "Hyperlipidemia is a key risk factor for cardiovascular disease, and it is associated with lipid metabolic disorders and gut microbiota dysbiosis." | ( A, L; Guo, R; Han, H; Li, Y; Ma, C; Shang, D; Sun, Z; Wang, H; Yang, C; Yang, F; Zhang, H; Zhang, L; Zhang, Y; Zhao, F, 2023) |
| "Dyslipidemias are linked to hemostatic alterations." | ( Aravena, C; Aravena, D; Echeverría, C; Eltit, F; Gatica, S; Llancalahuen, FM; Prado, Y; Riedel, CA; Simon, F, 2023) |
| "Control of hyperlipidemia is believed to reduce major cardiovascular events such as cardiovascular death, myocardial infarction, nonfatal stroke, hospitalization for unstable angina, and coronary revascularization." | ( Mohammed Ali, N; Yaseen, MS, 2022) |
| "Dyslipidemia is a well-established cardiovascular disease (CVD) risk factor, although its association with mortality is less clear." | ( Myers, J; Vainshelboim, B, 2023) |
| "Hyperlipidemia is the most well-known cause of metabolic complications and tissue toxicity such as liver steatosis, atherosclerosis and obesity." | ( Amrani, S; Hakmaoui, A; Harnafi, H; Harnafi, M; Milenkovic, D; Mokhtari, C; Mokhtari, I; Moumou, M, 2023) |
| Excerpt | Reference |
|---|
| "In order to study hyperlipidemia in diabetes mellitus, rats were made diabetic by administration of streptozotocin and the optimal conditions for production of severe and persistent hyperlipoprotenemia determined." | ( Bar-On, H; Eder, HA; Roheim, PS, 1976) |
| "From 30 cases of mixed hyperlipidemia which were resistant to apparently correctly managed treatment, combining an adapted diet and Clofibrate, the authors confirmed that there is no specific clinical or laboratory picture in these cases: except for the constant presence of two beta-lipoproteins, with a high percentage of slow pre-beta, on electrophoresis on agarose, persisting throughout the length of inactive treatment." | ( De Gennes, JL; Lambrozo, J; Truffert, J; Turpin, G, 1975) |
| "In a patient with type II hyperlipemia, the extravascular recycling pathway is reduced and is not corrected with D-thyroxine therapy." | ( Crespin, S; Eaton, RP; Kipnis, DM, 1976) |
| "One should never treat mixed hyperlipemia straightaway with hypocholesterolemic agents." | ( Cloarec, M; Cristol, R; Debray, J; Etienne, J; Graisely, B, 1976) |
| "70 patients with hyperlipemias of various types were treated perorally with 350 mg Mg-chlorophenoxyisobutyrate, and 250 mg of mesoinositol-hexanicotinate (Atroplex) three times daily." | ( Pistautz, H, 1977) |
| "It is concluded that clofibrate treatment of hyperlipidemia in uremic patients, when carefully monitored, is safe and efficacious." | ( Boulu, R; Crosnier, J; di Giulio, S; Drüeke, T; Nicolaĭ, A; Zingraff, J, 1977) |
| "Our data demonstrate that hyperlipidemia is a frequent finding in pediatric patients treated with MH and RT, and may be associated with premature coronary artery disease." | ( Fine, RN; Heuser, ET; Lipsey, A; Malekzadeh, MH; Mickey, MR; Pennisi, AJ, 1976) |
| "The treatment of both hyperlipidemia and hypertension appeared to be more effective than the treatment of hyperlipidemia, alone." | ( Hollander, W; Kirkpatrick, B; Madoff, I; Paddock, J, 1976) |
| "Hyperlipidemia was found to be ameliorated in nearly half of those patients after the start of diabetic treatment." | ( Abe, R; Maruhama, Y; Ohneda, A; Okuguchi, F, 1977) |
| "Hyperlipidemia appears to be a significant risk in the elderly, as in persons of any age, and should be treated accordingly." | ( Woldow, A, 1975) |
| "The most frequent indication for treatment of hyperlipidemia is for prevention of arteriosclerosis, a suspected but unproved benefit." | ( Gotto, AM; Yeshurun, D, 1976) |
| "In familial combined hyperlipidemia, however, and especially with concomitant thromboembolic disease, diet alone is often not sufficient, and drug treatment with anticoagulants and/or lipid-lowering drugs may be necessary." | ( Andersen, P, 1992) |
| "Treatment of hyperlipidemia was started by oral bezafibrate intake 1,200 mg per day in case 1 and 400 mg per day in case 2 respectively." | ( Inoue, M; Jimi, T; Machida, H; Niwa, Y; Wakayama, Y, 1992) |
| "Arguments against comprehensive treatment of hyperlipidemia have to do with the fact that although large interventional studies have shown a reduction in mortality from coronary heart disease, there has been no reduction in overall mortality." | ( Deller, M; Huth, K, 1992) |
| "Hyperlipidemia has received little attention as a side effect of cyclosporine therapy for severe psoriasis." | ( Davis, I; Jondreau, L; Kenny, C; Pak, GH; Shupack, JL; Stiller, MJ; Wachsman, S, 1992) |
| "By NCEP criteria for hyperlipidemia, 40% of family members met criteria for diet and/or pharmacological therapy." | ( Elbein, SC; Hunt, SC; Maxwell, TM; Schumacher, MC; Williams, RR; Wu, LL, 1992) |
| "In general, the prevalence of dyslipidemia in diabetic subjects remained higher than in nondiabetic subjects, despite hypoglycemic therapy." | ( Haffner, SM; Hazuda, HP; Mitchell, BD; Stern, MP, 1992) |
| "Controlling hyperlipidemia is an important aspect in the treatment and prevention of coronary artery disease." | ( Kuhn, M; Milander, MM, 1992) |
| "The value of treatment of hyperlipidemia in reducing the incidence of a first stroke remains to be demonstrated." | ( Bundlie, SR, 1991) |
| "Management of hyperlipidemia was assessed before and after the program via a self-administered questionnaire." | ( Horlick, L; Laxdal, OE; Reeder, BA, 1991) |
| "The severe hyperlipidemia in this patient was most likely induced by multiple interacting factors which included the metabolic abnormalities of nephrotic syndrome, steroid therapy, the underlying genetic predisposition of ApoE-2 homozygosity as well as diet and diuretic therapy." | ( Gregg, RE; Mann, WA; Ongkingco, JR; Ruley, EJ, 1991) |
| "Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats." | ( Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991) |
| "Efficacy was observed in 30 cases of hyperlipemia; 20 cases administered with evening primose oil capsules were taken as controls." | ( Guo, SS; Liang, XC, 1991) |
| "31 patients afflicted with primary hyperlipidemia who did not improve after 30 days on a diet were treated with 1800 mg/day of binifibrate." | ( Freixas Ventura, J; Gabriel Botella, F; Labiós Gómez, M; Martín Valles, H; Morera Llorca, M; Romero Simo, M, 1990) |
| "The pathogenesis of dyslipidemias differs between type I and type II diabetes: untreated type I diabetic subjects demonstrate frequently increased triglyceride concentrations due to diminished removal of triglyceride-containing particles, as a result of diminished activity of lipoprotein lipase." | ( Golay, A; Keller, U; Pometta, D, 1990) |
| "The hyperlipidemia had not been treated before, and a cholesterol-reduced diet did not succeed in lowering total cholesterol below 6." | ( Bauer, M; Hager, K; Platt, D, 1990) |
| "The serum-lipids were determined in 31 hyperlipemia patients before and after treated with the mixture of Acanthopanax senticosus and Elscholtzia splendens." | ( Li, R; Liu, C; Shi, Z, 1990) |
| "Twenty patients with hyperlipidemia not responding to dietary treatment received either one capsule of the active substance or of placebo (200 mg) three times daily for 16 weeks." | ( Avellone, G; Di Garbo, V; Strano, A, 1989) |
| "Five specific categories of dyslipidemia have been identified, with individualized screening and treatment strategies advised for each." | ( Assmann, G, 1988) |
| "Clinical therapy for hyperlipidemia and obesity mandates dietary changes." | ( Frank, GC, 1988) |
| "These tumor growth responses require hyperlipemia and are reversed by refeeding or insulin treatment, respectively." | ( Dauchy, RT; Sauer, LA, 1988) |
| "Treatment resulted in normolipidemia in 12 patients, who were hypercholesterolemic (7 type IIa, 3 type IIb, 2 type III hyperlipoproteinemia) prior to treatment." | ( Annuzzi, G; Holmquist, L; Wahlberg, G; Walldius, G, 1988) |
| "Hyperlipidemia should be managed systematically using information about the association between increased lipid concentrations and CAD, patient risk factors, and limitations of both diet and drug therapy." | ( Perry, RS, 1986) |
| "Hyperlipidemia is common after renal transplantation and has been attributed, at least in part, to corticosteroid therapy." | ( Brunner, FP; Hodel, K; Mordasini, RC; Thiel, G, 1986) |
| "Screening criteria for hyperlipidemia in normal patients and in special patient subgroups are described, and recommendations for treatment are proposed." | ( Scheidt, S, 1986) |
| "Treatment of hyperlipidemias must be commenced in that intestinal segment where alimentary lipoprotein aggregate generation is initiated postprandially and the aggregates are still in nascent form." | ( Setälä, K, 1986) |
| "Severe hyperlipidemia was nearly completely corrected in 16 diabetic patients who were treated with regular insulin at breakfast and supper." | ( Misra, SK; Turkington, RW, 1987) |
| "For almost all forms of hyperlipidemia, the first principle of dietary therapy is to reduce saturated fatty acids, decrease cholesterol, and curtail excess calories." | ( Grundy, SM, 1987) |
| "The dementia of a patient with hyperlipidemia improved dramatically on treatment with diet and fenofibrate." | ( Agar, N; Bousser, MG; Lacombe, C; Mas, JL, 1985) |
| "Detection and treatment of hyperlipidemia should of course also be initiated in the individual case in ordinary medical practice." | ( Kjellström, T; Lamme, S; Larsson, L; Mattiasson, I; Stavenow, L; Svensson, K; Trell, E; Tunestål, A, 1985) |
| "It is now clear that the various hyperlipidemias represent a heterogenous group of disorders, each having various clinical and laboratory characteristics, prognosis and treatment." | ( Mason, DT; Spann, JF; Zelis, R, 1970) |
| "Nine subjects with asymptomatic hyperlipidemia, hyperfibrinogenemia and exercise ST segment depressions were treated with clofibrate in order to lower plasma fibrinogen and serum lipids." | ( Blombäck, M; Ekelund, LG; Olsson, AG, 1980) |
| "Twenty-two patients suffering from hyperlipidemia and receiving therapy consisting of a lipid-lowering diet and clofibrate (1 g X 2) were in addition given colestipol hydrochloride (5 g X 3) (Colestid, Upjohn) in a randomized, cross-over study for 2 periods of 6 weeks." | ( Boberg, J; Hellsing, K; Lithell, H; Vessby, B, 1980) |
| "Treating hyperlipidemia in diabetics requires distinguishing between hypercholesterolemia, with its high risk of cardiovascular disease, and hypertriglyceridemia, which, if severe, may cause pancreatitis." | ( Saudek, CD, 1982) |
| "High-risk patients with dyslipidemias resistant to diet and single-agent pharmacotherapy may require combination therapy to achieve target levels of low density lipoprotein, triglycerides, and high density lipoprotein." | ( Hendricks, L; Khouri, HE; Latchinian, L; Munoz, CE; Spence, JD, 1995) |
| "We monitored hyperlipidemia in 20 hypercholesterolemic heart transplant patients receiving simvastatin 10 mg/d and triple-drug immunosuppressive therapy." | ( Campana, C; Gavazzi, A; Iacona, I; Montemartini, C; Perani, G; Raddato, V; Regazzi, MB; Viganò, M, 1995) |
| "Most children with familial hyperlipidemia did not reach desirable plasma lipid levels solely under diet therapy." | ( Assouline, L; Feoli-Fonseca, JC; Godbout, C; Lambert, M; Levy, E, 1995) |
| "To evaluate dietary therapy in the treatment of hyperlipidemia in patients with systemic lupus erythematosus (SLE)." | ( Baethge, BA; Broadwell, L; Hearth-Holmes, M; Wolf, RE, 1995) |
| "The incidence of severe hyperlipidemia during therapy of patients with acute lymphoblastic leukemia (ALL) who received prednisone and asparaginase was evaluated." | ( Steinherz, PG, 1994) |
| "Severe hyperlipidemia during induction therapy for ALL is random, transient, and benign." | ( Steinherz, PG, 1994) |
| "We treated hyperlipidemia in patients with nephrotic syndrome (NS) using pravastatin for more than one year." | ( Ishimoto, F; Matsuda, H; Matsumoto, H; Misawa, T; Nakano, H; Ohno, I; Sakai, O; Shibasaki, T, 1993) |
| "In summary, hyperlipidemia and glucose intolerance remain important metabolic consequences of renal transplantation that affect long-term patient survival unless recognized and treated." | ( Armenti, V; Danovitch, G; Markell, MS; Sumrani, N, 1994) |
| "61 aged with hyperlipidemia were randomly divided into treatment and control group according to the ratio of 2:1, which were treated with Youjiangzhi capsule and Mai-an Powder respectively." | ( Gao, P; Zhou, WQ, 1993) |
| "A 61-year-old woman with hyperlipidemia was treated with gemfibrozil." | ( Adler, Y; Aron, A; Weiss, P, 1993) |
| "Serum lipid levels in rats with hyperlipidemia induced by diet as well as by Triton were determined after oral administration of EtOAc extract of Pterocarpus marsupium heartwood and its flavonoid constituents, marsupsin [1], pterosupin [2], and liquiritigenin [3]." | ( Jahromi, MA; Ray, AB, 1993) |
| "While diet is the mainstay of treatment for hyperlipidemia, drug therapy is necessary to achieve treatment goals in certain patients." | ( Kantner, TR, 1993) |
| "Low-fat diets are widely recommended to treat hyperlipidemia and obesity and to reduce the risk of coronary heart disease, but concern has been expressed that they may not provide adequate calcium." | ( Ball, MJ; Upritchard, JE, 1996) |
| "Hyperlipidemia is a common side-effect of oral retinoid treatment, which sometimes interferes with long-term therapy." | ( Lindholm, A; Olsson, AG; Vahlquist, A; Vahlquist, C, 1995) |
| "For treatment and follow-up of hyperlipemia, 78% of physicians use cholesterol linked to low density lipoproteins (cLDL)." | ( Brea Hernando, AJ; Mosquera Lozano, JD; Ramírez Alesón, MV; Villar Arias, MA, 1996) |
| "Recent studies suggest that treating dyslipidemia in persons with coronary atherosclerosis may decrease morbidity and mortality." | ( Rembold, CM, 1996) |
| "Treatment of dyslipidemia in persons with multiple atherosclerosis risk factors alone, ie, primary prevention, was effective in preventing myocardial infarction and all-cause death." | ( Rembold, CM, 1996) |
| "In 17 patients with primary mixed hyperlipidemia we studied levels and composition of lipoproteins in fasting plasma, lipoprotein-modifying enzymes, and postprandial lipoprotein metabolism after an oral fat-tolerance test supplemented with vitamin A before, and 12 weeks after treatment with etophylline clofibrate." | ( Föger, B; Hopferwieser, T; Lechleitner, M; Menzel, HJ; Patsch, JR; Pfeiffer, KP; Ritsch, A; Tröbinger, G; Utermann, G, 1995) |
| "Niacin has been used for many years to treat hyperlipidemia." | ( Crouse, JR, 1996) |
| "We conclude: (1) posttransplant hyperlipidemia occurs less frequently in liver transplant patients than in renal or cardiac transplants; (2) pravastatin is safe and efficacious for cholesterol reduction in liver transplant patients; and (3) pravastatin coadministered with standard immunosuppression reduces natural killer cell-specific lysis in these recipients." | ( Busuttil, RW; Dawson, S; Goldstein, LI; Holt, CD; Imagawa, DK; Kaldas, FM; Kinkhabwala, MM; Kirk, PS; Martin, P; Murray, NG; Rudich, SM; Seu, P; Shackleton, CR; Terasaki, PI, 1996) |
| "Treatment of hyperlipidemia is addressed within the context of overall cardiovascular disease risk but also for stroke prevention." | ( Berglund, LF; Feinberg, W; Goldstone, J; Gorelick, PB; Schneck, M, 1997) |
| "Pravastatin treatment of combined hyperlipidemia lowers low-density lipoprotein effectively; nicotinic acid lowers remnant cholesterol and raises high-density lipoprotein." | ( Grundy, SM; Mostaza, JM; Schulz, I; Vega, GL, 1997) |
| "AD administration resulted in hyperlipidemia and high-grade proteinuria and a marked increase in serum lipoperoxides, urea, and creatinine." | ( López, A; Montilla, P; Muñoz, MC; Soria, JV; Túnez, I, 1997) |
| "With respect to dyslipidemia, 2 of the major challenges facing healthcare organizations are: (1) how to ensure continued monitoring and medication adherence for patients with known atherosclerosis (secondary prevention); and (2) how to select the high-risk patients who will most benefit from treatment from the larger population of individuals who have not had a known coronary event (primary prevention)." | ( Benson, VM, 1997) |
| "Treatment of dyslipidemia to prevent CHD depends on the pattern and severity of dyslipidemia, the presence of overt CHD, and the patient's response to diet." | ( Borgia, MC; Medici, F, 1998) |
| "The importance of treating dyslipidemias based on cardiovascular risk factors is highlighted by the National Cholesterol Education Program guidelines." | ( Ahmed, SM; Clasen, ME; Donnelly, JE, 1998) |
| "INSUFFICIENT PROGRESS: The treatment of hyperlipidemia leads to a reduced risk of coronary disease." | ( Luc, G, 1998) |
| "Hyperlipidemia is a widely acknowledged side effect of thiazide diuretic therapy, but it is often dismissed as a short-term effect of high-dose therapy." | ( Ames, R, 1998) |
| "He developed lipemia and green urine and subsequently, a progressive severe lactic acidemia and bradyarrhythmias unresponsive to conventional treatment." | ( Cox, PN; Cray, SH; Robinson, BH, 1998) |
| "Eighty-three patients with hyperlipidemia were treated with combined pravastatin and gemfibrozil therapy for a median of 44 months (range 9-78 months)." | ( Iliadis, EA; Rosenson, RS, 1999) |
| "Treatment of dyslipidemia and its frequently associated complications (manifest atherosclerosis) is very pretentious from the economic aspect." | ( Bartek, J; Franková, M; Horalík, D; Pastorková, R; Stejskal, D, 1998) |
| "As hyperlipidemia can modify some monocyte functions, we compared the TF and TFPI expression by circulating monocytes and the plasma TFPI levels between 65 healthy normolipemic controls and 38 nontreated hyperlipemic patients." | ( Bard, JM; Corseaux, D; Devos, P; Duriez, P; Gavériaux, V; Jude, B; Lecerf, JM; Rugeri, L; Susen, S, 1999) |
| "Prevention and treatment of dyslipidemias are major aims in the prevention of cardiovascular diseases." | ( de Lorgeril, M; Salen, P, 1999) |
| "Clinical BPH patients with hyperlipidemia may markedly benefit from terazosin, which is a safe and useful initial treatment for BPH." | ( Kageyama, S; Tamaki, M; Ueda, T, 1999) |
| "Among adults with hyperlipidemia, the presence of diabetes identifies men and women among whom lipid therapy is likely to be effective and cost-effective even in the absence of other risk factors or known cardiovascular disease." | ( Coupal, L; Dorais, M; Grover, SA; Zowall, H, 2000) |
| "Combination therapy for hyperlipidemia, especially combined hyperlipidemia, may have advantages over single drug therapy, affording better improvement in lipoprotein risk factors and possibly better prevention of atherothrombotic events." | ( Guyton, JR, 1999) |
| "The effects of statin therapy for hyperlipidemia on LV mass have not been studied." | ( Chu, CW; Hsiao, CL; Lee, BC; Lee, TM; Su, SF, 2000) |
| "We analysed the effect of hyperlipidemia and its treatment with gemfibrozil on platelet-fibrinogen binding and the development of early fibrinogen-rich vascular lesions in a porcine model of atherosclerosis." | ( Alfón, J; Badimon, L; Berrozpe, M; Royo, T, 2000) |
| "Prevalence of dyslipidemia (total cholesterolemia > or = 240 mg/dl or HDL-cholesterol < 35 mg/dl or currently receiving antihyperlipidemic therapy) increased significantly with increasing blood pressure in both sex (p < 0." | ( Bangou, J; Deloumeaux, J; Ekouévi, DK; Foucan, L; Haddad, A; Kangambega, P, 2000) |
| "Hyperlipidemia may complicate the use of HIV protease inhibitors (PIs) in AIDS therapy." | ( Croom, DK; Lenhard, JM; Weiel, JE; Winegar, DA, 2000) |
| "Effective treatment of dyslipidemia improves prognosis." | ( Alaswad, K; Moe, RM; O'Keefe, JH, 1999) |
| "Twenty subjects with mixed hyperlipidemia participated in a 3-arm crossover trial to evaluate the effectiveness of high-dose simvastatin as monotherapy." | ( Cromwell, W; Dolinar, C; Miller, M; Otvos, JD, 2001) |
| "Forty-nine middle-aged men with dyslipidemia and established CAD who were undergoing intensive lipid-lowering therapy were studied." | ( Brown, BG; Brunzell, JD; Deeb, SS; Hokanson, JE; Zambon, A, 2001) |
| "However, hyperlipidemia frequently develops in patients administered cyclosporine-based immunosuppression long-term, although it appears to occur less often with newer, tacrolimus-based regimens." | ( Braitman, LE; Levin, S; Manzarbeitia, C; Munoz, SJ; Reich, DJ; Rothstein, KD, 2001) |
| "Therefore, renal patients with dyslipidemia should be subjected to lipid-lowering therapy." | ( Quaschning, T; Wanner, C, 2001) |
| "Treatment of diabetic hyperlipidemia is important in order to reduce the incidence of cardiovascular events, which is high in type 2 diabetes." | ( Vergès, B, 2001) |
| "HYPERLIPIDEMIA: HIV-1 protease-inhibitors therapy is associated with increased levels of triglycerides, LDL-cholesterol and Lp(a)." | ( Petit, JM; Vergès, B, 2001) |
| "In patients with hyperlipidemia before therapy and in patients with coronary disease, no increase in diameter occurred (mean, 0." | ( Ceska, R; Haas, T; Spácil, J, 2001) |
| "Over the last three decades, hypolipemiants like fibric acid derivatives and statins have been increasingly recognised as causes of rhabdomyolysis and acute renal failure especially during combination therapy and in the presence of underlying renal impairment." | ( Kamaliah, MD; Sanjay, LD, 2001) |
| "91 patients with hyperlipidemia were randomly divided into a treatment group (n = 47, Xuezhikang 1." | ( Deng, C; Hao, X; Jian, J; Lin, J; Zhou, H, 1999) |
| "Hyperlipidemia has been frequently recorded as a side effect of treating HIV patients with protease inhibitors (PI)." | ( Caramelli, B; de Bernoche, CY; Monachini, MC; Santos, RD; Sartori, AM; Sposito, AC; Strabelli, T; Uip, D, 2001) |
| "We suggest that the control of hyperlipidemia can be a life-saving measure when combined with hyperglycemia control in the treatment of diabetes." | ( Kawazu, S; Komeda, K; Lu, D; Takeuchi, T; Zhang, W, 2002) |
| "Patients with combined dyslipidemia are at high risk for coronary artery disease and often require combination drug therapy to achieve lipid levels recommended by the US National Cholesterol Education Program's third Adult Treatment Panel (ATP III)." | ( Ballantyne, CM; Xydakis, AM, 2002) |
| "Atorvastatin treatment in diabetic dyslipidemia results in a significant dose-dependent decrease in HL activity, regardless of sex or the LIPC promoter variant." | ( Berk-Planken, II; Bootsma, AH; Hoogerbrugge, N; Jansen, H; Stolk, RP, 2003) |
| "Hyperlipidemia model was set up with administered high cholesterol emulsion 15 ml/kg to rats orally for 14 days." | ( Fu, ZG; He, K; Li, Q; Wu, T; Yang, Y; Zhang, JS, 1999) |
| "Patients of DM, with or without hyperlipidemia complication (HLC) were divided into 4 groups, Group A (33 cases without HLC) and B (33 cases with HLC) were treated by QDTMT, Group C (31 cases without HLC) and D (31 cases with HLC) were not treated by QDTMT." | ( Ma, SP; Wang, ZR; Zhang, M, 2001) |
| "Hyperlipidemia is a common problem and Atorvastatin is a safe and effective treatment in pediatric renal transplant recipients." | ( Aitken, M; Argent, E; Kainer, G; Mackie, FE; Rosenberg, AR, 2003) |
| "Combination therapy for dyslipidemia holds promise as effective treatment for patients with multiple lipid disorders, especially those at high risk." | ( Brazg, R; Hunninghake, DB; Koren, M; McGovern, ME; Murdock, D; Pearson, T; Weiss, S, 2003) |
| "Hyperlipidemia is a significant side effect of sirolimus treatment and often leads to vascular disease." | ( Abdel-Fattah, G; Kahan, BD; Morrisett, JD, 2003) |
| "Patients with combined hyperlipidemia and low high-density lipoprotein (HDL) cholesterol levels may benefit from combination therapy with a statin and niacin; therefore, we assessed the efficacy and safety of rosuvastatin and extended-release (ER) niacin alone and in combination in 270 patients with this atherogenic dyslipidemia." | ( Capuzzi, DM; Chitra, RR; Cressman, MD; Hutchinson, HG; Morgan, JM; Weiss, RJ, 2003) |
| "The mechanisms by which dyslipidemia and lipoatrophy develop during antiretroviral therapy are not clear." | ( Baldwin, C; Gazzard, BG; Langroudi, B; Mandalia, S; Moyle, GJ, 2003) |
| "Patients with combined hyperlipidemia (n = 37) were randomized to receive 9 weeks of treatment with micronized fenofibrate 200 mg/day (F group) or fenofibrate 200 mg/day plus folic acid 10 mg/every other day (F+F group)." | ( Ceska, R; Grauova, B; Haas, T; Hradec, J; Kozich, V; Krijt, J; Malik, J; Melenovsky, V; Stulc, T; Wichterle, D, 2003) |
| "Eighty-eight patients with hyperlipidemia were treated with simvastatin 5mg daily." | ( Ding, X; Shang, Y; Ye, P, 2003) |
| "Aggressive treatment of dyslipidemia and hypertension, even before the onset of type 2 diabetes, would appear prudent in decreasing the progression of the atherosclerotic process." | ( Hsueh, WA; Quiñones, MJ, 2003) |
| "Treatment of the dyslipidemia associated with type 2 diabetes and FCHL with a combination of a statin and a thiazolidinedione or niacin offers the most comprehensive modality to correct the various lipid abnormalities." | ( Ayyobi, AF; Brunzell, JD, 2003) |
| "Fibrates are widely used for treatment of hyperlipidemia." | ( Egashira, T; Inuzuka, S; Kinoshita, J; Kumamoto, M; Sata, M; Shishido, S; Tomiyasu, N; Ueno, T, 2003) |
| "In most patients with mixed hyperlipidemia and coronary heart disease (CHD) the treatment targeted both at triglyceride and LDL cholesterol levels is very difficult, when one lipid-lowering drug is used." | ( Białobrzeska-Paluszkiewicz, J; Grzybowska, B; Jakóbisiak-Ostasz, B; Kłosiewicz-Latoszek, L; Respondek, W; Stolarska, I, 2003) |
| "Furthermore, when prepared hyperlipemia rabbits were administered deep-sea water (desalinated water, hardness 28, 300, and 1200), there were no significant changes in aspartate aminotransferase (AST), alanine aminotransferase (ALT), high density lipoprotein cholesterol (HDL-Cho), or triglyceride (TG) levels." | ( Cui, T; Hamada, A; Kaneda, R; Kusunose, M; Kyotani, S; Miyamura, M; Nishioka, Y; Odani, I; Odani, K; Tsutsui, Y; Yamamoto, S; Yokota, J; Yoshioka, S, 2003) |
| "UAP patients with hyperlipidemia were treated with XZK 0." | ( Cui, CC; Wang, JK; Yao, QH, 2003) |
| "Treatment of the dyslipidemia associated with these disorders should focus on correcting the abnormal lipoprotein levels as well as LDL and HDL heterogeneity." | ( Ayyobi, AF; Brunzell, JD, 2003) |
| "The development of hyperlipidemia after liver transplant is frequently treated with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) such as atorvastatin." | ( Allen, J; Butler, M; Kubler, PA; Lynch, SV; Pillans, PI; Taylor, PJ, 2004) |
| "Gemfibrozil monotherapy of hyperlipidemia may predispose to rhabdomyolysis with acute renal failure." | ( Layne, RD; Sehbai, AS; Stark, LJ, 2004) |
| "In PMW with or without dyslipidemia, improvement in Lp(a) and other lipoproteins may represent cardiovascular benefits of hormone replacement therapy." | ( Ichikawa, S; Kumakura, H; Kurabayashi, M; Sakamaki, T; Sakamoto, H; Sawada, Y; Sumino, H; Takayama, Y, 2004) |
| "Little is known about the effect of dyslipidemia on serum uric acid (SUA) levels, and less is known about the effect of statin treatment on them." | ( Athyros, VG; Bouloukos, VI; Elisaf, M; Mikhailidis, DP; Milionis, HJ; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN, 2004) |
| "Even if CHD, dyslipidemia, and the treatment of these conditions has no role in preventing prostate cancer or its progression, what has been lost? CVD is still the leading cause of death of men, and a heart-healthy program for the patient concerned about prostate disease would reduce this primary cause of death." | ( Moyad, MA; Sonnleithner, M, 2004) |
| "Twenty Type 2 diabetic patients with dyslipidemia were treated 3 months with simvastatin (20 mg daily) and then 3 months with fenofibrate (200 mg daily) with 2 months of wash-out between the two treatments." | ( Ceska, R; Hilgertová, J; Kvasnicka, J; Skrha, J; Stulc, T; Weiserová, H, 2004) |
| "Although pharmacologic treatment for hyperlipidemia had the greatest favorable impact on the ratio over time, our data also show that maintaining an ideal weight and exercise have beneficial effects." | ( Buring, JE; Gaziano, JM; Levenson, JW; Scranton, R; Sesso, HD; Stampfer, MJ, 2004) |
| "This study compared efficacy of hyperlipidemia (HLE) correction by long-term hypolipidemic diet (HD) and pharmacotherapy (PT) in patients with ischemic heart disease (IHD)." | ( Mal', GS, 2004) |
| "Patients with dyslipidemias continue to be undertreated in both the primary and secondary prevention settings." | ( Davidson, MH; Toth, PP, 2004) |
| "Twenty patients with hyperlipidemia received statin (atorvastatin, 10 mg/day) therapy for 3 months." | ( Chu, CS; Lai, WT; Lee, KT; Sheu, SH; Tsai, LY; Voon, WC; Yen, HW, 2004) |
| "In patients with mixed hyperlipidemia, monotherapy with one of these agents may not be effective and combined treatment may be preferable." | ( Białobrzeska-Paluszkiewicz, J; Grzybowska, B; Kłosiewicz-Latoszek, L; Stolarska, I; Szostak, WB; Wiśniewska, B, 2004) |
| "Lack of folate supplementation, untreated hyperlipidemia, and elevated BMI identified patients receiving MTX at risk for transaminase elevation, and low serum albumin was a risk factor for thrombocytopenia." | ( Kent, PD; Luthra, HS; Michet, C, 2004) |
| "Sixty-three patients with type IIa dyslipidemia were randomized to fluvastatin (40 mg daily; n = 33) or simvastatin (20mg daily; n = 30), while 68 type IIb dyslipidemic patients were treated with micronized ciprofibrate (100mg daily; n = 34) or micronized fenofibrate (200mg daily; n = 34)." | ( Belowski, D; Herman, ZS; Kowalski, J; Krysiak, R; Labuzek, K; Madej, A; Okopień, B; Zieliński, M, 2004) |
| "We treated hyperlipidemia after renal transplantation with Fluvastatin for more than 6 months." | ( Akiba, T; Goya, N; Ishida, H; Ishikawa, N; Shimmura, H; Tanabe, K; Tokumoto, T; Toma, H, 2004) |
| "A total of 2,442 CHD patients with hyperlipidemia were randomized to either an aggressive treatment arm using atorvastatin or usual care and followed for 51." | ( Hunninghake, DB; Koren, MJ, 2004) |
| "Of the 67 patients diagnosed with hyperlipidemia, 33 (49%) were taking cholesterol-lowering medical therapy when admitted, and 38 (57%) were under treatment when discharged from the rehabilitation unit." | ( Basford, JR; Bogar, MD; Thomas, RJ, 2005) |
| "Atherogenic dyslipidemia is an important factor in cardiovascular risk in these patients, and treatment of atherogenic dyslipidemia has been identified as an important goal of therapy in patients with MS." | ( Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH, 2005) |
| "We investigated the effect of dyslipidemia associated with highly active antiretroviral therapy on cardiovascular risk and life expectancy among patients who had the human immunodeficiency virus." | ( Coupal, L; Gilmore, N; Grover, SA; Mukherjee, J, 2005) |
| "The prevalence of dyslipidemia and fasting hyperglycemia was significantly higher in the treatment groups." | ( Bhagat, S; Dravid, A; Nadler, JP; Naik, E; Pujari, SN; Sinnott, JT; Tash, K, 2005) |
| "As a treatment for dyslipidemia, oral doses of 1-3 grams of nicotinic acid per day lower serum triglycerides, raise high density lipoprotein cholesterol, and reduce mortality from coronary heart disease (Tavintharan, S." | ( Cai, TQ; Chen, R; Cheng, K; Connolly, D; Gan, X; Ippolito, M; Jin, L; Kaplan, R; Kero, J; Liaw, C; Offermanns, S; Ren, N; Richman, J; Taggart, AK; Waters, MG; Wright, SD; Wu, K; Wu, TJ, 2005) |
| "A total of 52 patients with hyperlipidemia were randomized to treatment with pravastatin (20 mg/day, n = 17), atorvastatin (20 mg/day, n = 18), or diet (n = 17) for six months." | ( Fujita, H; Fujiwara, H; Ito, Y; Kawasaki, M; Minatoguchi, S; Murata, I; Okubo, M; Sano, K; Tsuchiya, K; Yokoyama, H; Zhou, X, 2005) |
| "To determine a diagnosis of hyperlipidemia and the effectiveness of treatment, we assessed the patients's lipid levels." | ( Lynch, KJ; McKaveney, TP; Schonder, KS, 2005) |
| "Hyperlipemia rabbit models established with high cholesterol and fat diet were treated with direct moxibustion and medicinal cake-separated moxibustion." | ( Jie, Y; Jing, S; Shouxiang, Y; Xiangping, C; Xiaorong, C; Yaping, L; Zenghui, Y, 2005) |
| "Now hyperlipidemia is treated frequently with HMG-CoA reductase inhibitor, but there are few reports demonstrating lung injury by this drug." | ( Hisatomi, K; Ide, M; Ishii, H; Ishimoto, H; Kakugawa, T; Kohno, S; Mukae, H; Nakayama, S; Sugiyama, K; Yoshioka, S, 2005) |
| "Treatment of HIV dyslipidemia should include lifestyle modifications such as a low-fat diet, increased exercise, reduced alcohol consumption and smoking cessation." | ( Sax, PE, 2006) |
| "In treating hyperlipidemia in DM patients, combination of TZA with Sim 10 mg taken daily achieved satisfactory efficacy which was similar to Sim 20 mg daily alone." | ( Gao, F; Hu, XF, 2006) |
| "Since hyperlipidemia was also observed, oral administration of bezafibrate (400mg/day) alone was performed as the initial treatment, and transaminase, ALP, and GGT rapidly decreased." | ( Gondoh, K; Imamura, K; Miyakoda, K; Mukasa, M; Ono, T; Sata, M; So, A, 2006) |
| "Sixty cases of apoplexy with hyperlipidemia were randomly divided into a consciousness-restoring resuscitation acupuncture group (treatment group) and a Chinese medicine control group (control group), 30 cases in each group." | ( Han, JX; Jin, X; Liu, CZ; Lu, MX; Wang, T, 2006) |
| "Undertreatment of hyperlipidemia has received considerable attention." | ( Bartell, JM; Cox, ED; Smith, MA, 2006) |
| "Hyperlipidemia associated with clomiphene use is an uncommon but potentiallly serious complication of this therapy." | ( Burnett, JR; Gillett, MJ; Yeap, D, 2006) |
| "Hyperlipidemia is a recognized complication of HIV antiretroviral therapy." | ( Angel, JB; Cooper, CL; Mills, E, 2007) |
| "The incidence of hyperlipidemia in children is increasing in Japan, but drug therapy for such children is limited." | ( Hase, T; Kamimaki, I; Matsuyama, T; Otsuka, A; Shoji, K; Takase, H; Tanaka, Y; Tokimitsu, I; Watanabe, H, 2007) |
| "Food and Drug Administration for treatment of mixed hyperlipidemia." | ( Chun, P; Chung, S; Moon, YS, 2007) |
| "hyperlipidemia as a major risk factor of atherosclerosis is treated with different drugs." | ( Akrami, M; Kojuri, J; Vosoughi, AR, 2007) |
| "However, treatment of hyperlipidemia with statins reduces the probability of a CV event." | ( Carroll, L; Frazer, IH; Marwick, TH; Thomas, R; Turner, M, 2007) |
| "Since abnormal postprandial lipemia is associated with pathological conditions, its treatment is relevant." | ( Anagnostopoulou, KK; Daskalopoulou, SS; Kolovou, GD; Mikhailidis, DP; Salpea, KD, 2007) |
| "EGB pretreatment prevents hyperlipidemia and ameliorates lipid peroxidation induced by ethanol." | ( Li, K; Liu, L; Liu, S; Nussler, AK; Song, F; Sun, X; Yao, P; Zhou, S, 2007) |
| "After 24 hr of induction of hyperlipidemia in rats using poloxamer F127, administration of dry adsorbed emulsions effected significant reduction in the total cholesterol with levels of 439 mg/dL compared to 585 mg/dL of drug treated group (p < 0." | ( Dixit, RP; Nagarsenker, MS, 2007) |
| "The rats with established hyperlipidemia were then randomized into 4 groups and received every afternoon intragastric administration of high-dose (150 mg/kg) and low-dose (75 mg/kg) Qingzhi capsule, Xuezhikang (150 mg/kg, positive control ), and distilled water of the same volume (model group), respectively." | ( Chen, YY; Guo, YL; Tong, L, 2008) |
| "Since abnormal postprandial lipemia is associated with pathologic conditions, its treatment is of clinical importance." | ( Anagnostopoulou, KK; Cokkinos, DV; Kolovou, GD; Kostakou, PM, 2008) |
| "Hyperlipidemia and hyperhomocysteinemia was induced by methionine administration (1 g/kg, po) for 30 days." | ( Ansari, MN; Bhandari, U; Kapoor, P, 2008) |
| "Postprandial lipemia was induced by administration of whipping cream containing 33% fat (1 g fat/kg body weight)." | ( Abletshauser, C; Luley, C; Westphal, S, 2009) |
| "To assess the influence of hyperlipidemia (HL) on amiodarone (AM) effect in the heart, rats were pretreated with either 1 g/kg poloxamer 407 (to induce HL) or saline intraperitoneally." | ( Brocks, DR; Hamdy, DA, 2009) |
| "Phosphate-treated animals developed lipemia, hypercholesterolemia, anemia, higher serum fibrinogen levels, and lower serum albumin/globulin ratios on day 29." | ( Matsui, T; Narama, I; Torii, M; Tsuchiya, N, 2009) |
| "History of hyperlipidemia may have a negative impact on the outcomes of acute ischemic stroke treated with intra-arterial fibrinolysis or percutaneous mechanical embolectomy." | ( Ali, L; Bang, OY; Duckwiler, GR; Jahan, R; Kim, D; Liebeskind, DS; Ovbiagele, B; Restrepo, L; Saver, JL; Starkman, S; Vinuela, F, 2009) |
| "Eight hyperlipidemia rabbits were treated with the PVA-phosphate adsorbent, and the removal of TC, LDL and TG was 45." | ( Kong, D; Ou, L; Sun, L; Wang, L; Wang, W; Xie, H; Yu, Y, 2009) |
| "Metabolic changes during hyperlipidemia formation and improvement resulting from EGB treatment were definitively monitored with PCA score plots." | ( A, JY; Du, Y; Ma, B; Wang, GJ; Wu, D; Zhang, Q; Zhu, LL, 2009) |
| "Twenty patients with T2DM and hyperlipidemia were treated with 20 mg of simvastatin daily for 3 months, treatment was then interrupted for 3 months (wash-out) and again started and maintained continually up to total of 36 months of follow-up." | ( Kasalová, Z; Kvasnicka, J; Mazoch, J; Prázný, M; Skrha, J, 2009) |
| "Obese patients with primary hyperlipidemia (n=21) were administered 3000 mg/day of colestimide for 1 month and fasting blood was obtained before and after the treatment." | ( Chiba, H; Fujii, S; Kishimoto, N; Sakuma, I; Tsutsui, H, 2010) |
| "In simvastatin group, hyperlipidemia was induced by a 4-week administration of atherogenic diet followed by a 16-week treatment with simvastatin at the daily dose of 10 mg/kg, and the rats in hyperlipidemic rats received no treatment." | ( Chen, MS; He, ZC; Lu, DF; Wang, W; Wu, J; Xiao, Y, 2010) |
| "Although the mechanism of combined hyperlipidemia remains unknown and is not explained by fat consumption, hyperlipidemia is clearly progressive with age, suggesting that starting statin therapy early is probably beneficial." | ( Näntö-Salonen, K; Niinikoski, H; Simell, O; Tanner, LM, 2010) |
| "Use of pharmacotherapy for hyperlipidemia varied by ethnicity/race (chi2, p < 0." | ( Neumiller, JJ; Robison, LM; Sclar, DA; Skaer, TL; Willson, MN, 2010) |
| "Multiple-drug therapy of dyslipidemia is frequently used to achieve treatment goals in high-risk patients with coronary artery disease." | ( Phillips, W; Schaefer, S, 2010) |
| "Hyperlipidemia associated with the HIV protease inhibitor (PI), the major component of highly active antiretroviral treatment (HAART) for HIV infection, has stimulated interest in developing new agents that minimize these side effects in the clinic." | ( Cao, R; Gurley, EC; Hu, Y; Hylemon, PB; Pandak, WM; Sanyal, AJ; Studer, EJ; Wang, X; Wang, Y; Zhang, L; Zhou, H, 2010) |
| "Patients with mixed hyperlipidemia and at high risk of coronary heart disease may not achieve recommended low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) cholesterol goals on statin monotherapy." | ( Bryniarski, L; Ducobu, J; Farnier, M, 2010) |
| "Metformin did not affect postprandial lipemia and could be used to treat insulin resistance in this population." | ( Cabezas, MC; Dallinga-Thie, G; de Koning, EJ; Hoepelman, AI; Rabelink, TJ; van Wijk, JP, 2011) |
| "Treatment with rAPN inhibited hyperlipidemia-induced platelet aggregation (P<0." | ( Bai, QX; Gao, GX; Li, R; Wang, WQ; Wang, XM; Zhang, HF, 2011) |
| "Patients (n = 137) with dyslipidemia (not previously receiving statin therapy or having discontinued any lipid-altering treatment 4-5 weeks prior to the study) received NER/S (1000/40 mg/day for four weeks, then 2000/40 mg/day for eight weeks) or atorvastatin 40 mg/day for 12 weeks." | ( Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP, 2010) |
| "(Apocynaceae) is used to treat diabetes and hyperlipidemia in folk medicine." | ( Ignacimuthu, S; Pandikumar, P; Prakash Babu, N; Saravanan, M, 2011) |
| "Treatment of dyslipidemia in high-risk patients specifies a low-density lipoprotein (LDL) cholesterol <100 mg/dL." | ( Furman, A; Lopez, JR; Malmstrom, RA; Meier, JL; Schaefer, S, 2011) |
| "Rats were induced for hyperlipidemia and subjected to the drug treatment." | ( Bi, CW; Bi, K; Chen, X; Choi, RC; Dong, TT; Li, J; Ran, W; Tsim, KW; Wang, T, 2012) |
| "In this study, the NS and hyperlipidemia were ameliorated after 9 weeks administration of PMT." | ( Chen, J; Fu, W; Lei, Y; Ruan, J; Wu, G; Xiong, C; Zhang, Y, 2012) |
| "Atorvastatin treatment of lipemia was followed by a decrease in the total LP-C, total LDL-C (LDL(1-3)-C subfraction), and the LDL(1-3)-TG subfraction." | ( Cherkanova, MS; Filjushina, EE; Johnston, TP; Kaledin, VI; Korolenko, TA; Loginova, VM; Tuzikov, FV; Tuzikova, NA, 2012) |
| "Statin monotherapy for dyslipidemia only rarely achieves recommended target values of plasma lipids." | ( Vareka, T; Vecka, M; Vítková, D; Zák, A; Zeman, M, 2012) |
| "There was no need for further medical treatment of the hyperlipidemia." | ( Brox, J; Hansen, JB; Isaksen, V; Vik, A, 2012) |
| "However, unlike stroke, treatment of hyperlipidemia with statin class drugs or treatment of blood clotting abnormalities with acetylsalicylic acid do not appear to have an effect on VaD incidence or progression." | ( Baskys, A; Cheng, JX, 2012) |
| "Advantage of therapy secondary hyperlipidemia at children with diabetic ketoacidosis with use of Bifiform Baby consists in the elimination of the main infringement of a metabolismus of lipids in the given disease--hypertriglyceridemia." | ( Gonchar, NV; Il'ina, TV; Mel'nikova, IIu; Rudenko, NN; Udalova, AN, 2012) |
| "Among HIV-infected women, hyperlipidemia is most strongly associated with subclinical atherosclerosis in treated women." | ( Anastos, K; Benning, L; Gange, SJ; Hodis, HN; Kaplan, RC; Landay, AL; Lazar, J; Norris, PJ; Parrinello, CM; Tien, PC; Tracy, RP; Xue, X; Young, M, 2012) |
| "Transient hyperlipidemia in kittens has been previously reported and successfully treated with administration of oxygen, blood transfusion, and diet change; these treatment recommendations may not always be financially feasible, resulting in euthanasia of affected kittens." | ( Bauer, JE; Blackstock, KJ; Diep, AN; Schoeffler, G; Wakshlag, JJ, 2012) |
| "However, the efficacy of berberine in treating hyperlipidemia should be further evaluated by more randomized controlled trials in a larger population of patients." | ( Dong, H; Lu, F; Zhao, L; Zhao, Y, 2013) |
| "The effects of IGA-CDP on a hyperlipidemia mouse model were studied by intragastric administration." | ( Diao, GW; Liu, C; Sun, Y; Wang, Q; Zhang, W, 2013) |
| "The hyperlipidemia model was established by intro-gastric administration of fat emulsion for 4 weeks in the later four groups, and 0." | ( Ji, MY; Wang, LL; Zhang, HF; Zhou, XY, 2013) |
| "Hyperlipidemia is associated with an increased risk of cardiovascular events; reducing low-density lipoprotein cholesterol (LDL-C), the primary target for cholesterol-lowering therapy, lowers the risk for such events." | ( Jones, MR; Nwose, OM, 2013) |
| "The pathophysiology of hyperlipidemia is important in the proper selection of drug therapy." | ( Wu, AH, 2014) |
| "Forty-two primary hyperlipidemia patients were randomly divided into two groups of 21 and treated with moxibustion at different temperatures." | ( Ye, X; Zhang, H, 2013) |
| "We stratified patients with hyperlipidemia according to the risk categories outlined by the Adult Treatment Panel III of the National Cholesterol Education Program." | ( Ballantyne, CM; Blom, DJ; Bolognese, M; Burgess, L; Ceska, R; Hala, T; Kim, JB; Koren, MJ; Lillestol, MJ; Monsalvo, ML; Roth, E; Scott, R; Stein, EA; Toth, PD; Tsirtsonis, K; Wasserman, SM, 2014) |
| "Hdber is effective in the treatment of hyperlipidemia in rats." | ( Chen, G; Dong, H; Huang, ZY; Liu, DL; Lu, FE; Luo, YH; Wang, KF; Xu, LJ; Zou, X, 2015) |
| "Hyperlipidemia and insulin resistance were attenuated effectively in response to GTS treatment." | ( Guo, HF; Hu, MY; Li, F; Li, J; Li, Y; Liu, C; Liu, L; Liu, XD; Xu, P; Zhang, J; Zhang, M, 2014) |
| "A well-balanced diet is the first-line treatment in hyperlipidemia." | ( Baila-Rueda, L; Bea, AM; Cenarro, A; Civeira, F; De Castro-Orós, I; Mateo-Gallego, R; Moreno, LA; Mouratidou, T; Perez-Calahorra, S, 2015) |
| "Totally 138 combined hyperlipidemia patients were randomly assigned to the combined treatment group (A) and the atorvastatin treatment group (B) by random digit table, 69 in each group." | ( Guan, XH; Guo, WS; He, YB; Pan, AQ; Wang, JX; Xie, Y; Zhang, J; Zhang, SX, 2014) |
| "Statins are recommended first-line treatment for hyperlipidemia, with published studies suggesting limited differences between them." | ( Bishop, I; Campbell, SM; Godman, B; Malmström, RE; Truter, I, 2015) |
| "Because hypothyroidism and hyperlipidemia developed at different time points of treatment and among different patients, our results failed to demonstrate a correlation between these adverse events." | ( Baldazzi, V; Carini, M; Lapini, A; Mazzanti, R; Tassi, R, 2015) |
| "As for the treatment of hyperlipidemia, berberine with lifestyle intervention was better than lifestyle intervention, berberine with oral lipid lowering drugs was better than lipid lowering drugs alone in reducing the level of TC and LDL-C, and raising the level of HDL-C." | ( Dong, F; Fan, J; Lan, J; Sun, G; Yan, Z; Zhao, Y; Zheng, W, 2015) |
| "(group 1: normal diet control; group 2: hyperlipemia model; group 3: hyperlipemia mice treated with Coreopsis tinctoria, low dose 100 mg/kg; group 4: hyperlipemia mice treated with Coreopsis tinctoria high dose group 200 mg/kg; group 5 hyperlipemia mice treated with Fenofibrate." | ( Chen, X; Li, Y; Liu, J; Wulasihan, M; Xue, J, 2014) |
| "Tinnitus, in patients having hyperlipidemia, can be successfully dealt with by treating hyperlipidemia with lipid lowering agent atorvastatin." | ( Ahmed, A; Hameed, MK; Najam, A; Sheikh, ZA, 2014) |
| "Agonist treatment induced hyperlipidemia in low fat fed rats and this effect was amplified in high fat fed rats." | ( Baranowski, M; Chabowski, A; Górski, J; Harasiuk, D; Zabielski, P, 2015) |
| "HU was administered to these hyperlipidemia rats for 30 days." | ( Qi, H; Sheng, J, 2015) |
| "It is not only a safe and effective treatment of hyperlipidemia, but it also reduces inflammatory markers and atherosclerosis." | ( Ahmed, MH; Elmadhoun, WM; Hassan, AT; Husain, NE, 2015) |
| "Hyperlipidemia treatment based on niacin requires gastrointestinal administration of relatively high doses." | ( Hobzova, R; Hrib, J; Hromadka, R; Michalek, J; Sandrikova, V; Sirc, J; Slanar, O; Stankova, B; Vetrik, M; Zak, A, 2015) |
| "A total of 218 patients with hyperlipidemia were selected and treated with 10 mg rosuvastatin per day for 12 weeks." | ( Lin, J; Wang, W; Wang, X; Zhang, Y; Zhou, H, 2015) |
| "HFD induced hyperlipidemia mice were administrated with triterpene and non-triterpene fractions at doses of 180, 360 and 720 mg/kg body weight/day for 4 weeks, respectively." | ( Chen, C; Feng, Y; Jiang, H; Jin, S; Li, S; Song, C; Wan, Q; Xiang, Y; Xu, Y; Zhang, Y, 2016) |
| "The hyperlipidemia mice treated with the triterpene fraction showed a significant decrease in serum TC, LDL-C and AI after continuous consumption of HFD for 4 weeks." | ( Chen, C; Feng, Y; Jiang, H; Jin, S; Li, S; Song, C; Wan, Q; Xiang, Y; Xu, Y; Zhang, Y, 2016) |
| "Rutaecarpine ameliorates hyperlipidemia and hyperglycemia in fat-fed, streptozotocin-treated rats via regulating IRS-1/PI3K/Akt signaling pathway in liver and AMPK/ACC2 signaling pathway in skeletal muscles." | ( Bian, K; Chen, HH; He, YQ; Murad, F; Nie, XQ; Pan, HJ; Song, WX; Yang, JW; Zhang, JY; Zhang, YJ, 2016) |
| "To induce hyperlipidemia, some of the rats were administered intraperitoneal doses of poloxamer 407 before giving an oral dose of dronedarone." | ( Brocks, DR; Jardan, YA, 2016) |
| "Wistar rats with hyperlipidemia induced by high-fructose diet (60%) were treated for 60 days with water, simvastatin (30 mg·Kg(-1)), ciprofibrate (2 mg·Kg(-1)), and ExC (200 mg·Kg(-1))." | ( Alfredo, TM; Antunes, KÁ; da Rocha, Pdos S; de Picoli Souza, K; Dos Santos, EL; Espindola, PP; Lopes, RH; Macorini, LF; Pereira, ZV, 2016) |
| "Hypertension and hyperlipidemia are important risk factors for CVD that are modifiable by pharmacological treatment and life-style changes." | ( Cook, S; Cybulsky, M; Kontsevaya, AV; Leon, DA; Vasiljev, M, 2016) |
| "Prevalence of hyperlipidemia was 45 % (age-standardised prevalence 40 %), however less than 2 % of those with hyperlipidemia were taking any treatment." | ( Cook, S; Cybulsky, M; Kontsevaya, AV; Leon, DA; Vasiljev, M, 2016) |
| "The prevalence of hypertension and hyperlipidemia is high in Izhevsk while the proportion of those treated and attaining treatment targets is very low." | ( Cook, S; Cybulsky, M; Kontsevaya, AV; Leon, DA; Vasiljev, M, 2016) |
| "It may also prove to be beneficial in treatment of hyperlipidemia and other cardiovascular conditions." | ( Nanda, RK; Poddar, SS; Shetane, TD; Shirsat, A; Singha, RG; Thomas, AB, 2017) |
| "Hyperlipidemia mice were orally administered with SCL (100 mg/kg) once a day for 4 weeks." | ( Chen, JG; Cong, LX; Li, H; Liu, X; Sun, JH; Wang, CM; Zhang, CY, 2017) |
| "In conclusion, HCHF-induced hyperlipidemia caused adverse effects on the bone that were rescued by paeoniflorin treatment." | ( Chai, Y; Hu, C; Lu, S; Wang, Y; Zhong, W; Zhu, Y, 2018) |
| "Hyperlipidemia was induced in rats through the administration of a high-fat diet (HFD)." | ( Guo, R; Ma, X; Nie, C; Wang, Z; Xiao, X; Xu, H; Zhang, F; Zhao, L; Zhou, S, 2018) |
| "To investigate the mechanism of the treatment of hyperlipidemia rats induced by Huangqi San." | ( Dang, YX; Gao, Y; Hao, MJ; Li, WM; Wang, CY; Zhou, XX, 2018) |
| "Female Chinese patients with hyperlipidemia carrying rs717620 GA/AA genotypes might have reduced benefit from simvastatin treatment." | ( Cai, Y; Hu, M; Hu, Z; Jia, C; Liu, N; Yang, G; Zhang, M, 2018) |
| "For this purpose, hyperlipidemia was induced by administration of Cholesterol (90% E, Appli Chem, Darmstadt, Germany) mixed at dose of 400 mg/kg body weight of rats in their daily routine feed." | ( Ahmad, RS; Ahmad, U; Arshad, MS; Hameed, A; Hussain, SM; Mushtaq, Z, 2018) |
| "The hyperlipidemia patients were further divided into two groups (Sensitive and Resistant Group) according to their clinical response to Atorvastatin therapy." | ( Dong, B; Kou, L; Li, Y; Qin, Q; Song, Y; Yang, J; Yang, N, 2018) |
| "Aggressive treatment of hyperlipidemia should be carefully considered in these patients although it could reduce the risk of atherosclerotic cardiovascular diseases and stroke recurrence in some stroke patients." | ( Huang, WY; Lung, YJ; Weng, WC; Wu, CL, 2019) |
| "Hyperlipidemia was induced in Sprague‑Dawley rats (male, 6‑7 months old) by consuming a high‑fat diet, and rats were divided into three groups (n=10 each) and underwent: exploratory laparotomy to introduce surgical trauma (surgery group), laparotomy and Dex treatment (surgery+Dex group), or sham surgery (sham group)." | ( Chai, M; Han, M; Li, DB; Liu, YR; Wang, G; Yang, HT; Zhang, XP, 2019) |
| "Experimental hyperlipidemia mice are treated with or without tanshinol A (i." | ( Cai, D; Chen, Y; Gan, H; Hu, Z; Huang, D; Huang, X; Jiang, J; Li, R; Li, Y; Xie, K; Yao, N; Zhan, X, 2020) |
| "Antiplatelet therapy moderated the hyperlipidemia induced by HFD-C in the current study." | ( Korish, AA, 2020) |
| "This review summarizes the role of hyperlipidemia in ASCVD and treatment strategies for hyperlipidemia in the CKD population." | ( Bangalore, S; Chaudhry, R; Costa, SP; Lyubarova, R; Mathew, RO; Rosenson, RS; Sidhu, MS, 2021) |
| "Hyperlipidemia is closely associated with various liver diseases, and effective intervention for prevention and treatment is in great need." | ( Cao, K; Liu, J; Liu, X; Lv, W; Wang, K; Yang, M, 2020) |
| "It is clinically used in the treatment of hyperlipidemia with significant curative effect." | ( Jiang, Y; Li, L; Lin, T; Liu, B; Zhang, J; Zhang, Y, 2021) |
| "Statins play an important role in the treatment of hyperlipidemia, but drug resistance and adverse effects greatly limits their application." | ( Chen, W; Cheng, H; Ge, H; Xie, Y; Xu, X; Xue, H; Yang, P; Yuan, K; Zhang, J; Zhang, W, 2021) |
| "At least 3 patients exhibited hyperlipidemia at baseline; in 2 of them, this was caused by previous fluoropyrimidine treatment." | ( Komatsu, Y; Saito, Y; Sugawara, M; Takekuma, Y; Takeuchi, S, 2021) |
| "Nondiabetic patients with dyslipidemia were prospectively randomized (1:1) either to the MNT group or the control group with standard advice for 48 weeks with simultaneous statin/ezetimibe combination pharmacotherapy at three tertiary centers in Korea." | ( Bae, JH; Chang, Y; Jang, JY; Jeong, SW; Kim, HS; Kim, SG; Kim, YS; Lee, SH; Lee, WM; Moon, JE; Yoo, JJ, 2021) |
| "After confirmation of hyperlipidemia, treatment was started for the next 14 days." | ( Jaiswal, A; Semwal, BC; Singh, S, 2023) |
| "Patients with a confirmed history of lipemia retinalis were grouped into two cohorts based on their most recent fundus examination: untreated lipemia retinalis (abnormal fundus) and resolved lipemia retinalis (normal fundus)." | ( Al Adel, FF; Al Malawi, RM; Alamri, A; AlBloushi, AF; Alsarhani, WK, 2022) |
| "Patients with untreated lipemia retinalis had a significantly higher retinal arteriolar and venular oxygen saturation than that of the other two groups (p < 0." | ( Al Adel, FF; Al Malawi, RM; Alamri, A; AlBloushi, AF; Alsarhani, WK, 2022) |
| "High-fat diet (HFD) induced hyperlipidemia rats were administrated with different doses of QZC for 28 days, and atorvastatin calcium tablets was used as the positive control." | ( Fang, H; Han, Y; Ren, J; Song, H; Sun, H; Wang, X; Yan, G; Yang, L, 2023) |
| "is used to prevent and treat dyslipidemia, coronary heart disease, etc." | ( Cao, Q; Duan, ZW; Hu, XH; Huang, SL; Li, X; Wei, SL; Zhang, PP; Zhang, Y; Zhao, T; Zhuo, BY, 2023) |
| "Hyperlipidemia, a common metabolic disease, is a risk factor for cardiovascular diseases, Poria cocos (PC) and Alismatis rhizoma (AR) serve as a potential treatment." | ( Li, X; Lin, S; Liu, X; Luo, J; Ren, Q; Wang, Y; Yan, Z; Zhou, X, 2023) |